CA2101356C - Improvements in or relating to benzothiophenes - Google Patents
Improvements in or relating to benzothiophenesInfo
- Publication number
- CA2101356C CA2101356C CA002101356A CA2101356A CA2101356C CA 2101356 C CA2101356 C CA 2101356C CA 002101356 A CA002101356 A CA 002101356A CA 2101356 A CA2101356 A CA 2101356A CA 2101356 C CA2101356 C CA 2101356C
- Authority
- CA
- Canada
- Prior art keywords
- medicament
- compound
- preparation
- treatment
- raloxifene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
The current invention provides compounds, methods and pharmaceutical formulations for use in treating or preventing osteoporosis by inhibiting the loss of bone.
These compounds, methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus are effective in the prevention or treatment of osteoporosis.
These compounds, methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus are effective in the prevention or treatment of osteoporosis.
Description
IMPROVEMENTS IN OR RELATING TO BENZOTHIOPHENES
This invention relates to the discovery that a group of 2-phenyl-3-aroylbenzothiophenes is useful in the prevention of bone loss.
The mechanism of bone loss is not well understood, but in practical effect, the disorder arises from an imbalance in the formation of new healthy bone and the resorption of old bone, skewed toward a net loss of bone tissue. This bone loss includes a decrease in both mineral content and protein matrix components of the bone, and leads to an increased fracture rate of, predominantly, femoral bones and bones in the forearm and vertebrae.
These fractures, in turn, lead to an increase in general morbidity, a marked loss of stature and mobility, and, in many cases, an increase in mortality resulting from complications.
Bone loss occurs in a wide range of subjects, including post-menopausal women, patients who have undergone hysterectomy, patients who are undergoing or have undergone long-term administration of corticosteroids, patients suffering from Cushing's syndrome, and patients having gonadal dysgensis.
unchecked, bone loss can lead to osteoporosis, a major debilitating disease whose prominent feature is the ~ 5 ~
loss of bone mass (decreased density and enlargement of bone spaces) without a reduction in bone volume, producing porosity and fragility.
one of the most common types of osteoporosis is found in post-menopausal women affecting an estimated 20 to 25 million women in the United States alone. A significant feature of post-menopausal osteoporosis is the large and rapid loss of bone mass due to the cessation of estrogen production by the ovaries. Indeed, data clearly support the ability of estrogens to limit the progression of osteoporotic bone loss, and estrogen replacement is a recognized treatment for post-menopausal osteoporosis in the United States and many other countries. However, although estrogens have beneficial effects on bone, given even at very low levels, long-term estrogen therapy has been implicated in a variety of disorders, including an increase in the risk of uterine and breast cancer, causing many women to avoid this treatment. Recently suggested therapeutic regimens, which seek to lessen the cancer risk, such as administering combinations of progestogen and estrogen, cause the patient to experience regular withdrawal bleeding, which is unacceptable to most older women. Concerns over the significant undesirable effects associated with estrogen therapy, and the limited ability of estrogens to reverse existing bone loss, support the need to develop alternative therapy for bone loss that ''~-generates the desirable effects on bone but does not cause undesirable effects.
Attempts to fill this need by the use of compounds commonly known as antiestrogens, which interact with the estrogen receptor, have had limited success, perhaps due to the fact that these compounds generally display a mixed agonist/antagonist effect. That is, although these compounds can antagonize estrogen interaction with the receptor, the compounds themselves may cause estrogenic responses in those tissues having estrogen receptors. Therefore, some antiestrogens are subject to the same adverse effects associated with estrogen therapy.
The current invention provides methods for inhibiting the loss of bone without the associated adverse effects of estrogen therapy, and thus serves as an effective and acceptable treatment for osteoporosis.
The 2-phenyl-3-aroylbenzothiophene compounds that are the active component in the formulations and methods of this invention were first developed by C. David Jones and Tulio Suarez as anti-fertility agents (see U.S.
Patent No. 4,133,814, issued January 9, 1979). Certain compounds in the group were found to be useful in suppressing the growth of m~mm~ry tumors.
Jones later found a group of related compounds to be useful for antiestrogen and antiandrogen therapy, especially in the treatment of m~mm~ry and prostatic tumors _ X-7947 -4- ~ 3 ~ 6 (see U.S. Patent 4,418,068, issued November 29, 1983). One of these compounds, the compound of formula I wherein n is 0, R and R1 are hydroxyl, and R2 is a piperidino rin~, was clinically tested for a brief time for the treatment of breast cancer. That compound is called raloxifene, formerly keoxifene. When administered for therapy, raloxifene is preferably in the salt form, most preferably as the hydrochloride salt.
S~MMARY OF THE INVENTION
This invention provides the use of a compound of formula I
~ OCH2CH2-(CH2)n- R2 ~~
R~
, (I) wherein n is 0, 1 or 2;
~-F '~
X-7947 -5- ~ 3 ~ ~
R and R1, independently, are hydrogen, hydroxyl, Cl-C6-alkoxy, Cl-c6-acyloxy~ Cl-C6-alkoxy-C2-C6-acyloxy, R3-substituted aryloxy, R3-substituted aroyloxy, R4-substituted carbonyloxy, chloro, or bromo;
R2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino;
R3 is C1-C3-alkyl, C1-C3-alkoxy, hydrogen, or halo; and R4 is C1-C6-alkoxy or aryloxy; or a pharmaceutically acceptable thereof; in the treatment or prevention of osteoporosis in a human.
The invention also provides a pharmaceutical formulation for use in inhibiting bone loss comprising a compound of formula I, wherein R, R1, R2, and n are as defined supra, in an amount that increases or retains bone density, together with a pharmaceutically acceptable carrier.
The current invention concerns the discovery that a group of 2-phenyl-3-aroylbenzothiophenes (benzothiophenes) of formula I are useful in the treatment of osteoporosis. The benzothiophenes of formula I inhibit the loss of bone that results from a lack of endogenous estrogen such as occurs in women following cessation of menstruation due to natural, surgical, or other processes.
The reduction of bone density and mass that more rarely 3 ~ ~
occurs in men is also tied to the loss of hormonal regulation and is the~efore also a target for therapy according to the methods of the current invention.
The benzothiophenes of fo-mula I are a series of nonsteroidal compounds that exhibit high a~finity for conventional estrogen receptors in primary sex target tissues. However, they elicit minimal estrogenic responses in those tissues, and actually serve as potent antagonists of natural estrogens such as estradiol. The benzothiophenes of formula I are able to antagonize classical estrogenic responses in primary sex target tissues without significantly reducing bone density when given to intact or estrogen treated animals, and they prevent bone loss in estrogen deficient animals. This dichotomy indicates selective agonist/antagonist actions on specific target cells which would appear to be highly desirable in treatment of the menopausal syndrome.
Accordingly, the real benefit of the current discovery is that the benzothiophenes of formula I inhibit the loss of bone but do not elicit significant estrogenic responses in the primary sex target tissues. Thl~s, th~ current invention provides the use of a compound of formula I as defined previously for inhibiting bone loss in a human in need of treatment, in an amount that inhibits bone loss but which does not significantly affect the primary sex target tissues. This combination of features allows for long-term ~, , treatment of the chronic ailment with a diminished risk of developing the undesirable effects of customary estrogen replacement therapy.
The biological action of the benzothiophenes of formula I is complex and may be unrelated to the detectable presence of the parent compound in the blood. Following oral administration of a preferred benzothiophene of this invention, raloxifene (administered as the hydrochloride salt), to human subjects in the clinic, the parent compound was not detected in the serum of those subjects. It was determined that following oral administration, the compound was extensively conjugated to the glucuronidated form and cleared quickly from the bloodstream. Although no biological endpoints were measured in the human recipients, there was concern that the compound was not bioavailable.
Experiments were undertaken to address the bioavailability issue in laboratory animals where biological activity could be assessed. The animal studies indicated that raloxifene was maximally active in inhibiting both uterine uptake of tritiated-estradiol and the normal uterotrophic response to estradiol, even under conditions where raloxifene was extensively conjugated in the plasma of the animals. Moreover, the conjugate, isolated from the urine of the human subjects treated with raloxifene, displayed significant antiestrogenic/
antiuterotrophic activity when administered intravenously 3 5 ~
to rats, and inhibited the interaction of tritiated-estradiol with rat uterine estrogen receptors in a manner similar to the parent compound. These studies suggested the conjugated compound may have been converted to the parental form at the site of action, presumably by the action of ~-glucuronidase. Such conversion may contribute to the activity of the compound. ~-Glucuronidase is fairly ub~quitous, is thought to be active in the resorption process of bonè remodeling, and would presumably be available for converting the conjugated compound to the parental form if required for activity. Therefore, conjugation of the benzothiophenes of formula I is not considered to be necessarily detrimental to their bioavailability as an inhibitor of bone loss.
lS Thus, the method of treatment provided by this invention is practiced by administering to a human in need of inhibition of bone loss, a dose of a compound of formula I or a pharmaceutically acceptable salt thereof, that is effective to inhibit bone loss. A particular benefit of this method is that it avoids potentially harmful and unacceptable estrogenic side effects. The inhibition of bone loss contemplated by the present method includes both medical therapeutic and/or prophylactic treatment, as appropriate.
The invention also includes the administration of a medicament provided by the use of a compound of formula I
in combination with estrogen.
,..~,, 3 ~ ~
X-7947 _9_ The term estrogen as used herein refers to any compound which approximates the spectrum of activities of the naturally acting molecule which is commonly believed to be 17~-estradiol. Examples of such compounds include estriol, estrone, ethynyl estradiol,''Premarinllfa commercial preparation of conjugated estrogens isolated from natural sources - Ayerst), and the like. Again, due to the selective agonist/antagonist properties of the compounds of formula I, this combination provides for the full benefits of estrogen therapy without the concomitant adverse effects associated with estrogen therapy alone.
The general chemical terms used in the description of a compound of formula I have their usual meanings. For example, the term l~Cl-C3-alkyl'' includes lS such groups as methyl, ethyl, propyl, and isopropyl.
The term "Cl-C6-alkoxy" includes such groups as methoxy, ethoxy, propoxy, butoxy, pentyloxy, and hexyloxy and also includes branched chain structures such as, for example, isopropoxy and isobutoxy.
The term ~Cl-C6-acyloxy~ includes methanoyloxy, ethanoyloxy, propanoyloxy, butanoyloxy, pentanoyloxy, hexanoyloxy, and the like and also includes branched chain structures such as, for example, 2,2-dimethylpropanoyloxy, and 3,3-dimethylbutanoyloxy.
The term "Cl-C6-alkoxy-C2-C6-acyloxy"
contemplates, for example, methoxyethanoyloxy, * Trademark .,~
methoxypropanoyloxy, methoxybutanoyloxy, methoxy-pentanoyloxy, methoxyhexanoyloxy, ethoxyethanoyloxy, ethoxypropanoyloxy, ethoxybutanoyloxy, ethoxypentanoyloxy, ethoxyhexanoyloxy, propoxyethanoyloxy, propoxypropanoyloxy, propoxybutanoyloxy, and the like.
It should also be understood that as used herein, references to alkyl and alkoxy structures also include cycloalkyl and cycloalkoxy groups where the number of carbons within the structure is at least 3.
The terms ~R3-substituted aryloxy~l and ~R3-substituted aroyloxy~ include such groups as phenyloxy, thienyloxy, furyloxy, naphthyloxy, benzoyloxy, thienoyloxy, furoyloxy, naphthoyloxy, and the like, where the R3 substitution group may be hydrogen, hydroxyl, Cl-C3-alkyl, Cl-C3-alkoxy, or halo.
The term ~R4-substituted carbonyloxy, where the R4 substitution group may be Cl-C6-alkoxy or aryloxy, includes carbonate structures such as methoxycarbonyloxy ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, pentyloxycarbonyloxy, hexyloxycarbonyloxy, phenyloxy-carbonyloxy, thienyloxycarbonyloxy, furyloxycarbonyloxy, and naphthyloxycarbonyloxy.
Preferred embodiments of this invention comprise the use of compounds of formula I wherein R and Rl are other than hydrogen, alkoxy, aryloxy, chloro, or bromo and therefore represent ester and carbonate configurations.
Other preferred embodiments include the use of formula I
compounds wherein R and Rl are the same. Certain R2 groups also demonstrate preferable characteristics when used in the embodiments of this invention. For example, preferred embodiments of this invention include the use of formula compounds wherein R2 is piperidino or pyrrolidino, especially piperidino. A further preferred subgroup of the piperidino and pyrrolidino compounds includes compounds wherein R and Rl are other than hydrogen and, in particular, those wherein R and Rl are hydroxyl. The most preferred embodiment of the invention involves the use of raloxifene, especially when administered as the hydrochloride salt.
All of the compounds used in the methods of the current invention can be made according to established procedures, such as those detailed in U.S. Patent No.
4,133,814 and u.S. Patent No. 4,418,068. In general, the process starts with a benzo[b]thiophene having a 6-hydroxyl group and a 2-(4-hydroxyphenyl) group. The starting compound is protected, alkylated, and deprotected to form the formula I compounds wherein R and Rl are both hydroxy.
The formula I compounds that are ethers, esters, and carbonates may then be formed if desired. Examples of the preparation of such compounds are provided in the U.S.
patents discussed above. Specific preparations of yet other derivatized compounds useful in the current invention 21~l3~
are outlined in the Preparations sections below.
Modifications to the above methods may be necessary to accommodate reactive functionaiities of particular substituents. Such modifications would be both apparent to, and readily ascertained by, those skilled in the art.
The compounds used in the methods of this invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry.
Such salts are also part of this invention. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, ~-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, 3 5 ~
x-7947 -13-hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene-sulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methane-sulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like.
In addition, some of the formula I compounds may form solvates with water or organic solvents such as ethanol. These solvates are also contemplated for use in the methods of this invention.
The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth '~., .,~
5 L s~ ~i3 metal hydroxides, carbonates and bicarbonates, as well as aliphatic and aromatic amines, aliphatic diamines and hydroxy alkylamines. sases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylene diamine, cyclohexylamine and ethanolamine.
The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
The current invention also provides pharmaceutical formulations useful for inhibiting bone loss comprising a formula I compound, or a pharmaceutically acceptable salt thereof, plus one or more pharmaceutically acceptable excipients. Pharmaceutical formulations can be prepared by procedures known in the art. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as -glycerol; disintegrating agents such as agaragar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethylene glycols.
The compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like.
The formulations can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
The particular dosage of a compound of formula I
required to treat or inhibit bone loss according to this invention will depend upon the severity of the disease, its route of administration, and related factors that will be decided by the attending physician. Generally, an effective dose will be from about 0.1 to about 1000 mg of the formula I compound, typically from about 50 to about S
400 mg, and most preferably about 50 to about 200 mg. Such dosages will be administered to a subject in need of treatment from once to about three times each day, or more often as needed to effectively inhibit the bone loss process.
It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the adminlstration of pharmaceuticals bearing a basic group such as the piperidino ring. It is also advantageous to administer such a compound by the oral route to an aging human (e.g. a post-menopausal female or a male showing evidence of bone loss by X-ray analysis). For such purposes the following oral dosage forms are available.
Formulations In the formulations which follow, ~Active ingredient'~ means a compound of formula I.
This invention relates to the discovery that a group of 2-phenyl-3-aroylbenzothiophenes is useful in the prevention of bone loss.
The mechanism of bone loss is not well understood, but in practical effect, the disorder arises from an imbalance in the formation of new healthy bone and the resorption of old bone, skewed toward a net loss of bone tissue. This bone loss includes a decrease in both mineral content and protein matrix components of the bone, and leads to an increased fracture rate of, predominantly, femoral bones and bones in the forearm and vertebrae.
These fractures, in turn, lead to an increase in general morbidity, a marked loss of stature and mobility, and, in many cases, an increase in mortality resulting from complications.
Bone loss occurs in a wide range of subjects, including post-menopausal women, patients who have undergone hysterectomy, patients who are undergoing or have undergone long-term administration of corticosteroids, patients suffering from Cushing's syndrome, and patients having gonadal dysgensis.
unchecked, bone loss can lead to osteoporosis, a major debilitating disease whose prominent feature is the ~ 5 ~
loss of bone mass (decreased density and enlargement of bone spaces) without a reduction in bone volume, producing porosity and fragility.
one of the most common types of osteoporosis is found in post-menopausal women affecting an estimated 20 to 25 million women in the United States alone. A significant feature of post-menopausal osteoporosis is the large and rapid loss of bone mass due to the cessation of estrogen production by the ovaries. Indeed, data clearly support the ability of estrogens to limit the progression of osteoporotic bone loss, and estrogen replacement is a recognized treatment for post-menopausal osteoporosis in the United States and many other countries. However, although estrogens have beneficial effects on bone, given even at very low levels, long-term estrogen therapy has been implicated in a variety of disorders, including an increase in the risk of uterine and breast cancer, causing many women to avoid this treatment. Recently suggested therapeutic regimens, which seek to lessen the cancer risk, such as administering combinations of progestogen and estrogen, cause the patient to experience regular withdrawal bleeding, which is unacceptable to most older women. Concerns over the significant undesirable effects associated with estrogen therapy, and the limited ability of estrogens to reverse existing bone loss, support the need to develop alternative therapy for bone loss that ''~-generates the desirable effects on bone but does not cause undesirable effects.
Attempts to fill this need by the use of compounds commonly known as antiestrogens, which interact with the estrogen receptor, have had limited success, perhaps due to the fact that these compounds generally display a mixed agonist/antagonist effect. That is, although these compounds can antagonize estrogen interaction with the receptor, the compounds themselves may cause estrogenic responses in those tissues having estrogen receptors. Therefore, some antiestrogens are subject to the same adverse effects associated with estrogen therapy.
The current invention provides methods for inhibiting the loss of bone without the associated adverse effects of estrogen therapy, and thus serves as an effective and acceptable treatment for osteoporosis.
The 2-phenyl-3-aroylbenzothiophene compounds that are the active component in the formulations and methods of this invention were first developed by C. David Jones and Tulio Suarez as anti-fertility agents (see U.S.
Patent No. 4,133,814, issued January 9, 1979). Certain compounds in the group were found to be useful in suppressing the growth of m~mm~ry tumors.
Jones later found a group of related compounds to be useful for antiestrogen and antiandrogen therapy, especially in the treatment of m~mm~ry and prostatic tumors _ X-7947 -4- ~ 3 ~ 6 (see U.S. Patent 4,418,068, issued November 29, 1983). One of these compounds, the compound of formula I wherein n is 0, R and R1 are hydroxyl, and R2 is a piperidino rin~, was clinically tested for a brief time for the treatment of breast cancer. That compound is called raloxifene, formerly keoxifene. When administered for therapy, raloxifene is preferably in the salt form, most preferably as the hydrochloride salt.
S~MMARY OF THE INVENTION
This invention provides the use of a compound of formula I
~ OCH2CH2-(CH2)n- R2 ~~
R~
, (I) wherein n is 0, 1 or 2;
~-F '~
X-7947 -5- ~ 3 ~ ~
R and R1, independently, are hydrogen, hydroxyl, Cl-C6-alkoxy, Cl-c6-acyloxy~ Cl-C6-alkoxy-C2-C6-acyloxy, R3-substituted aryloxy, R3-substituted aroyloxy, R4-substituted carbonyloxy, chloro, or bromo;
R2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino;
R3 is C1-C3-alkyl, C1-C3-alkoxy, hydrogen, or halo; and R4 is C1-C6-alkoxy or aryloxy; or a pharmaceutically acceptable thereof; in the treatment or prevention of osteoporosis in a human.
The invention also provides a pharmaceutical formulation for use in inhibiting bone loss comprising a compound of formula I, wherein R, R1, R2, and n are as defined supra, in an amount that increases or retains bone density, together with a pharmaceutically acceptable carrier.
The current invention concerns the discovery that a group of 2-phenyl-3-aroylbenzothiophenes (benzothiophenes) of formula I are useful in the treatment of osteoporosis. The benzothiophenes of formula I inhibit the loss of bone that results from a lack of endogenous estrogen such as occurs in women following cessation of menstruation due to natural, surgical, or other processes.
The reduction of bone density and mass that more rarely 3 ~ ~
occurs in men is also tied to the loss of hormonal regulation and is the~efore also a target for therapy according to the methods of the current invention.
The benzothiophenes of fo-mula I are a series of nonsteroidal compounds that exhibit high a~finity for conventional estrogen receptors in primary sex target tissues. However, they elicit minimal estrogenic responses in those tissues, and actually serve as potent antagonists of natural estrogens such as estradiol. The benzothiophenes of formula I are able to antagonize classical estrogenic responses in primary sex target tissues without significantly reducing bone density when given to intact or estrogen treated animals, and they prevent bone loss in estrogen deficient animals. This dichotomy indicates selective agonist/antagonist actions on specific target cells which would appear to be highly desirable in treatment of the menopausal syndrome.
Accordingly, the real benefit of the current discovery is that the benzothiophenes of formula I inhibit the loss of bone but do not elicit significant estrogenic responses in the primary sex target tissues. Thl~s, th~ current invention provides the use of a compound of formula I as defined previously for inhibiting bone loss in a human in need of treatment, in an amount that inhibits bone loss but which does not significantly affect the primary sex target tissues. This combination of features allows for long-term ~, , treatment of the chronic ailment with a diminished risk of developing the undesirable effects of customary estrogen replacement therapy.
The biological action of the benzothiophenes of formula I is complex and may be unrelated to the detectable presence of the parent compound in the blood. Following oral administration of a preferred benzothiophene of this invention, raloxifene (administered as the hydrochloride salt), to human subjects in the clinic, the parent compound was not detected in the serum of those subjects. It was determined that following oral administration, the compound was extensively conjugated to the glucuronidated form and cleared quickly from the bloodstream. Although no biological endpoints were measured in the human recipients, there was concern that the compound was not bioavailable.
Experiments were undertaken to address the bioavailability issue in laboratory animals where biological activity could be assessed. The animal studies indicated that raloxifene was maximally active in inhibiting both uterine uptake of tritiated-estradiol and the normal uterotrophic response to estradiol, even under conditions where raloxifene was extensively conjugated in the plasma of the animals. Moreover, the conjugate, isolated from the urine of the human subjects treated with raloxifene, displayed significant antiestrogenic/
antiuterotrophic activity when administered intravenously 3 5 ~
to rats, and inhibited the interaction of tritiated-estradiol with rat uterine estrogen receptors in a manner similar to the parent compound. These studies suggested the conjugated compound may have been converted to the parental form at the site of action, presumably by the action of ~-glucuronidase. Such conversion may contribute to the activity of the compound. ~-Glucuronidase is fairly ub~quitous, is thought to be active in the resorption process of bonè remodeling, and would presumably be available for converting the conjugated compound to the parental form if required for activity. Therefore, conjugation of the benzothiophenes of formula I is not considered to be necessarily detrimental to their bioavailability as an inhibitor of bone loss.
lS Thus, the method of treatment provided by this invention is practiced by administering to a human in need of inhibition of bone loss, a dose of a compound of formula I or a pharmaceutically acceptable salt thereof, that is effective to inhibit bone loss. A particular benefit of this method is that it avoids potentially harmful and unacceptable estrogenic side effects. The inhibition of bone loss contemplated by the present method includes both medical therapeutic and/or prophylactic treatment, as appropriate.
The invention also includes the administration of a medicament provided by the use of a compound of formula I
in combination with estrogen.
,..~,, 3 ~ ~
X-7947 _9_ The term estrogen as used herein refers to any compound which approximates the spectrum of activities of the naturally acting molecule which is commonly believed to be 17~-estradiol. Examples of such compounds include estriol, estrone, ethynyl estradiol,''Premarinllfa commercial preparation of conjugated estrogens isolated from natural sources - Ayerst), and the like. Again, due to the selective agonist/antagonist properties of the compounds of formula I, this combination provides for the full benefits of estrogen therapy without the concomitant adverse effects associated with estrogen therapy alone.
The general chemical terms used in the description of a compound of formula I have their usual meanings. For example, the term l~Cl-C3-alkyl'' includes lS such groups as methyl, ethyl, propyl, and isopropyl.
The term "Cl-C6-alkoxy" includes such groups as methoxy, ethoxy, propoxy, butoxy, pentyloxy, and hexyloxy and also includes branched chain structures such as, for example, isopropoxy and isobutoxy.
The term ~Cl-C6-acyloxy~ includes methanoyloxy, ethanoyloxy, propanoyloxy, butanoyloxy, pentanoyloxy, hexanoyloxy, and the like and also includes branched chain structures such as, for example, 2,2-dimethylpropanoyloxy, and 3,3-dimethylbutanoyloxy.
The term "Cl-C6-alkoxy-C2-C6-acyloxy"
contemplates, for example, methoxyethanoyloxy, * Trademark .,~
methoxypropanoyloxy, methoxybutanoyloxy, methoxy-pentanoyloxy, methoxyhexanoyloxy, ethoxyethanoyloxy, ethoxypropanoyloxy, ethoxybutanoyloxy, ethoxypentanoyloxy, ethoxyhexanoyloxy, propoxyethanoyloxy, propoxypropanoyloxy, propoxybutanoyloxy, and the like.
It should also be understood that as used herein, references to alkyl and alkoxy structures also include cycloalkyl and cycloalkoxy groups where the number of carbons within the structure is at least 3.
The terms ~R3-substituted aryloxy~l and ~R3-substituted aroyloxy~ include such groups as phenyloxy, thienyloxy, furyloxy, naphthyloxy, benzoyloxy, thienoyloxy, furoyloxy, naphthoyloxy, and the like, where the R3 substitution group may be hydrogen, hydroxyl, Cl-C3-alkyl, Cl-C3-alkoxy, or halo.
The term ~R4-substituted carbonyloxy, where the R4 substitution group may be Cl-C6-alkoxy or aryloxy, includes carbonate structures such as methoxycarbonyloxy ethoxycarbonyloxy, propoxycarbonyloxy, butoxycarbonyloxy, pentyloxycarbonyloxy, hexyloxycarbonyloxy, phenyloxy-carbonyloxy, thienyloxycarbonyloxy, furyloxycarbonyloxy, and naphthyloxycarbonyloxy.
Preferred embodiments of this invention comprise the use of compounds of formula I wherein R and Rl are other than hydrogen, alkoxy, aryloxy, chloro, or bromo and therefore represent ester and carbonate configurations.
Other preferred embodiments include the use of formula I
compounds wherein R and Rl are the same. Certain R2 groups also demonstrate preferable characteristics when used in the embodiments of this invention. For example, preferred embodiments of this invention include the use of formula compounds wherein R2 is piperidino or pyrrolidino, especially piperidino. A further preferred subgroup of the piperidino and pyrrolidino compounds includes compounds wherein R and Rl are other than hydrogen and, in particular, those wherein R and Rl are hydroxyl. The most preferred embodiment of the invention involves the use of raloxifene, especially when administered as the hydrochloride salt.
All of the compounds used in the methods of the current invention can be made according to established procedures, such as those detailed in U.S. Patent No.
4,133,814 and u.S. Patent No. 4,418,068. In general, the process starts with a benzo[b]thiophene having a 6-hydroxyl group and a 2-(4-hydroxyphenyl) group. The starting compound is protected, alkylated, and deprotected to form the formula I compounds wherein R and Rl are both hydroxy.
The formula I compounds that are ethers, esters, and carbonates may then be formed if desired. Examples of the preparation of such compounds are provided in the U.S.
patents discussed above. Specific preparations of yet other derivatized compounds useful in the current invention 21~l3~
are outlined in the Preparations sections below.
Modifications to the above methods may be necessary to accommodate reactive functionaiities of particular substituents. Such modifications would be both apparent to, and readily ascertained by, those skilled in the art.
The compounds used in the methods of this invention form pharmaceutically acceptable acid and base addition salts with a wide variety of organic and inorganic acids and bases and include the physiologically acceptable salts which are often used in pharmaceutical chemistry.
Such salts are also part of this invention. Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the like. Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, may also be used. Such pharmaceutically acceptable salts thus include acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, ~-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, caprate, caprylate, chloride, cinnamate, citrate, formate, fumarate, glycollate, heptanoate, 3 5 ~
x-7947 -13-hippurate, lactate, malate, maleate, hydroxymaleate, malonate, mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate, phthalate, terephthalate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate, propionate, phenylpropionate, salicylate, sebacate, succinate, suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite, sulfonate, benzene-sulfonate, p-bromophenylsulfonate, chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate, methane-sulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, p-toluenesulfonate, xylenesulfonate, tartarate, and the like.
In addition, some of the formula I compounds may form solvates with water or organic solvents such as ethanol. These solvates are also contemplated for use in the methods of this invention.
The pharmaceutically acceptable acid addition salts are typically formed by reacting a compound of formula I with an equimolar or excess amount of acid. The reactants are generally combined in a mutual solvent such as diethyl ether or benzene. The salt normally precipitates out of solution within about one hour to 10 days and can be isolated by filtration or the solvent can be stripped off by conventional means.
Bases commonly used for formation of salts include ammonium hydroxide and alkali and alkaline earth '~., .,~
5 L s~ ~i3 metal hydroxides, carbonates and bicarbonates, as well as aliphatic and aromatic amines, aliphatic diamines and hydroxy alkylamines. sases especially useful in the preparation of addition salts include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylene diamine, cyclohexylamine and ethanolamine.
The pharmaceutically acceptable salts generally have enhanced solubility characteristics compared to the compound from which they are derived, and thus are often more amenable to formulation as liquids or emulsions.
The current invention also provides pharmaceutical formulations useful for inhibiting bone loss comprising a formula I compound, or a pharmaceutically acceptable salt thereof, plus one or more pharmaceutically acceptable excipients. Pharmaceutical formulations can be prepared by procedures known in the art. For example, the compounds can be formulated with common excipients, diluents, or carriers, and formed into tablets, capsules, suspensions, powders, and the like. Examples of excipients, diluents, and carriers that are suitable for such formulations include the following: fillers and extenders such as starch, sugars, mannitol, and silicic derivatives; binding agents such as carboxymethyl cellulose and other cellulose derivatives, alginates, gelatin, and polyvinyl pyrrolidone; moisturizing agents such as -glycerol; disintegrating agents such as agaragar, calcium carbonate, and sodium bicarbonate; agents for retarding dissolution such as paraffin; resorption accelerators such as quaternary ammonium compounds; surface active agents such as cetyl alcohol, glycerol monostearate; adsorptive carriers such as kaolin and bentonite; and lubricants such as talc, calcium and magnesium stearate, and solid polyethylene glycols.
The compounds can also be formulated as elixirs or solutions for convenient oral administration or as solutions appropriate for parenteral administration, for instance by intramuscular, subcutaneous or intravenous routes. Additionally, the compounds are well suited to formulation as sustained release dosage forms and the like.
The formulations can be so constituted that they release the active ingredient only or preferably in a particular part of the intestinal tract, possibly over a period of time. The coatings, envelopes, and protective matrices may be made, for example, from polymeric substances or waxes.
The particular dosage of a compound of formula I
required to treat or inhibit bone loss according to this invention will depend upon the severity of the disease, its route of administration, and related factors that will be decided by the attending physician. Generally, an effective dose will be from about 0.1 to about 1000 mg of the formula I compound, typically from about 50 to about S
400 mg, and most preferably about 50 to about 200 mg. Such dosages will be administered to a subject in need of treatment from once to about three times each day, or more often as needed to effectively inhibit the bone loss process.
It is usually preferred to administer a compound of formula I in the form of an acid addition salt, as is customary in the adminlstration of pharmaceuticals bearing a basic group such as the piperidino ring. It is also advantageous to administer such a compound by the oral route to an aging human (e.g. a post-menopausal female or a male showing evidence of bone loss by X-ray analysis). For such purposes the following oral dosage forms are available.
Formulations In the formulations which follow, ~Active ingredient'~ means a compound of formula I.
2 ~ 3 Formulation 1: Gelatin Capsules Hard gelatin capsules are prepared using the following:
IngredientQuantity (mg/capsule) Active ingredient 0.1 - 1000 Starch, NF 0 - 650 Starch flowable powder0 - 650 Silicone fluid 350 centistokes 0 - 15 The ingredients are blended, passed through a ~o. 45 mesh u.S. sieve, and filled into hard gelatin capsules.
Examples of specific capsule formulations containing raloxifene, as the hydrochloride salt, that have been made include those shown below:
Formulation 2: Raloxifene capsule IngredientQuantity (mg/capsule) Raloxifene hydrochloride Starch, NF 112 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 3: Raloxifene capsule IngredientQuantity (mg/capsule) Raloxifene hydrochloride 5 Starch, NF 108 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 4: Raloxifene capsule IngredientQuantity (mg/capsule) Raloxifene hydrochloride 10 Starch, NF 103 Starch flowable powder225.3 Silicone fluid 350 centistokes 1.7 Formulation 5: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene hydrochloride 50 Starch, NF 150 Starch flowable powder 397 Silicone fluid 350 centistokes 3.0 The specific formulations above may be changed in compliance with the reasonable variations provided.
A tablet formulation is prepared using the ingredients below:
Formulation 6: Tablets Ingredient Quantity (~.g/tablet) Active ingredient 0.1 - lO00 Cellulose, microcrystalline0 - 650 Silicon dioxide, fumed 0 - 650 Stearic ac~d 0 - 15 The components are blended and compressed to form tablets.
, I
.. ~, ~3~
x-7947 -19-Alternatively, tablets each containing 0.1 -1000 mg of active ingredient are made up as follows:
Formulation 7: Tablets Ingredient Quantity (mg/tablet) Active in~redient 0.1 - 1000 Starch 45 Cellulose, microcrystalline 35 Polyvinylpyrrolidone 4 (as 10% solution in water) Sodium carboxymethyl cellulose 4.5 Magnesium stearate 0.5 Talc The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50~-60~ C and passed through a No. 18 mesh U.S. sieve.
The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
Suspensions each containing 0.1 - 1000 mg of medicament per 5 mL dose are made as follows:
Formulation 8: Suspensions Ingredient Quantity (mg/5 ml) Active ingredient 0.1 - 1000 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 mL
Flavor q.v.
Color q.v.
Purified water to 5 mL
The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
Illustrative compounds that can be used in the formulations and methods of this invention are shown in Table 1.
2 i ~ 6 _ Tabl e Compound No. n R and Rl R2 Form 1 0-OC(O) ~ F piperidino base 2 0-OC(O) ~ F piperidino HCl 3 o-OC(O) ~ piperidino base 4 0-OC(O) ~ piperidino HCl o. -OC(O)CH2CH2CH3 piperidino base 6 0-OC(O)CH2CH2CH3 piperidino HCl 7 o-OC(O)C(CH3)3 piperidino base 8 0-oc(o)C(CH3)3 piperidino HCl 9 0-OC(O)CH2C(CH3)3 piperidino base 0-Oc(O)CH2C(CH3)3 piperidino HCl 11 0-OC(O) ~ CH3 piperidino HCl 12 0-OC(O) ~ piperidino base 13 0-oc(o)ocH2cH2cH2cH3 piperidino base 14 0-OC(O)OCH2CH2CH2CH3 piperidino HCl 0-OC(O)O ~ piperidino base 16 0-OC(O)O ~ piperidino HCl 17 0-OC(O) ~ piperidino base 18 0-OC(O)CH2CH20CH3 piperidino base 19 0-OC(O)CH2CH20CH3 piperidino HCl 0 OH piperidino base 3 ~ ~
-Table 1 (cont. ) Compound No. n R and R1 R2 Form 21 0 OH piperidino HC1 22 0 H piperidino base 23 1 OH piperidino HCl 24 2 OH piperidino HC1 1 H piperidino HC1 26 0 OH pyrrolidino base 27 0 o~ pyrrolidino HC1 28 1 OH pyrrolidino HC1 29 2 OH pyrrolidino HC1 0 H pyrrolidino HC1 31 0 OH hexamethyleneimino HC1 32 1 OH hexamethyleneimino HCl 33 2 OH hexamethyleneimino HCl 34 0 OCH3 piperidino HCl -In the following Preparations, the compound numbers correspond to those given in Table 1 Pre~aration 1 Preparation of Compound 1:
6-(4-Fluorobenzoyloxy)-2-[4-(4-fluorobenzoyloxy)phenyl]-benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone.
Raloxifene hydrochloride (also called, 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-l-yl)ethoxyphenyl]-methanone hydrochloride), (5.1 g, 10 mmol) was suspended in 250 mL of dry tetrahydrofuran (THF) and 7.1 g (70 mmol) of triethylamine, and approximately 10 mg of 4-(N,N-dimethylamino)pyridine were added. The suspension was cooled in an ice bath and placed under an atmosphere of nitrogen. 4-Fluorobenzoyl chloride (4.75 g, 30 mmol), dissolved in 20 mL of dry THF, was slowly added over a twenty minute period. The reaction mixture was stirred and allowed to slowly warm to room temperature over a period of eighteen hours. It was then filtered, and the filtrate was evaporated to a gum in vacuo. The crude product thus obtained was dissolved in a small volume of chloroform and chromatographed (HPLC) on a silica gel column eluted with a linear gradient of solvent, starting with chloroform and ending with a mixture of ~1û13~
.
chloroform-methanol (19:1 (v/v)). The fractions containing the desired product as determined by thin layer chromatography (silica, chloroform-methanol (9:1)) were combined and evaporated to a gum. The final product was crystallized from ether to give 3.21 g of compound 1.
PMR: consistent with the structure FDMS: m/e - 717 M+
Elemental Analysis for C42H33F2NO6S:
Theor: C, 70.29; H, 4.60; N, 1.95 Found: C, 70.05; H, 4.60; N, 1.89 Mol. wt.: 717 Pre~aration 2 Preparation of Compound 2:
6-(4-Fluorobenzoylo.Yy)-2-[4-(4-fluorobenzoyloxy)-phenyl]-benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]-phenyl]-methanone hydrochloride.
Compound 1 (5.15 g, 7.18 mmol) was dissolved in 25 mL THF, and 150 mL ether was added. Dry HCl gas was bubbled into the solution, and a white gummy precipitate formed. The liquid was removed by decanting, and the residue was crystallized from ethyl acetate with a small amount of ethanol added to effect solution. The product 2 ~
-was filtered, washed with ether, and dried to give 4.41 g of Compound 2 as a white powder.
PMR: consistent with the structure Elemental Analysis for C42H34clF2NO6s:
Theor: C, 66.88; H, 4.54; N, 1.86 Found: C, 66.59, H, 4.39; N, 1.60 Mol. Wt.: 753.5 Pre~aration 3 Preparation of Compound 3:
6-(Cyclopropylcarbonyloxy)-2-[4-(cyclopropylcarbonyloxy)-phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
The title compound was prepared using procedures analogous to those in Preparation 1, but using cyclopropylcarbonyl chloride, except that the product was not crystallized. Yield = 2.27 g.
PMR: consistent with the structure FDMS: m/e = 610 M+
' -Preparation 4 Preparation of Compound 4:
6-(Cyclopropylcarbonyloxy)-2-[4-(cyclopropylcarbonyloxy)-phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone hydrochloride.
Compound 4 was prepared from Compound 3 as described in Preparation 2.
Preparation 5 Preparation of Compound 5: - .
6-(n-Butanoyloxy)-2-[4-(n-butanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone.
Compound 5 was prepared using the method of Preparation 1, but starting with n-butanoyl chloride, to give 4.12 g of final product as an oil.
PMR. consistent with the structure FDMS: m/e = 614 (M+l) 2 1 ~
._ x-7947 -27-Pre~aration 6 Preparation of Compound 6:
6-(n-Butanoyloxy)-2-[4-(n-butanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride.
Compound 5 (4.12 g) was dissolved in ethyl acetate (50 mL), and a solution of HCl in ether was added until the precipitation stopped. The liquid was decanted off, and the white, gummy residue was triturated with diethyl ether and filtered. The residue was dried to give 1.33 g of Compound 6.
PMR: consistent with the structure Elemental Analysis of for C36H40ClNO6S:
Theor.: C, 66.50; H, 6.20; N, 2.15 Found: C, 66.30; H, 6.28; N, 1.98 Mol. Wt.: 650.24 3 ~ ~
Preparation 7 Preparation of Compound 7:
6-(2,2-Dimethylpropanoyloxy~-2-[4-(2,2-dimethyl-propanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone.
Compound 7 was prepared using the procedure of Preparation 1, but using 2,2-dimethylpropanoyl chloride.
Preparation 8 Preparation of Compound 8:
6-(2,2-Dimethylpropanoyloxy)-2-[4-(2,2-dimethyl-propanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride.
Compound 8 was prepared from Compound 7, as described in Preparation 2.
FDMS: m/e = 641 (M-HCl-l) Elemental Analysis of C3gH44ClN06S:
Theor.: C, 67.29; H, 6.54i N, 2.07 Found: C, 67.02; H, 6.54; N, 1.90 Mol. Wt.: 678.29 21Ql~
Preparation 9 Preparation of Compound 9:
6-(3,3-Dimethylbutanoyloxy)-2-[4-(3,3-dimethylbutanoyloxy)-phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
Compound 9 was prepared using the procedures of Preparation 1, but with 3,3-dimethylbutanoyl chloride.
Pre~aration 10 Preparation of Compound 10:
6-(3,3-Dimethylbutanoyloxy)-2-[4-(3,3-dimethylbutanoyloxy)-phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone hydrochloride.
Compound 10 was prepared from Compound 9 as described in Preparation 2.
FDMS: m/e = 669 (M-HCl-l) Elemental Analysis of C40H4gClN06S:
Theor.: C, 68.02; H, 6.85; N, 1.98 Found: C, 67.75; H, 6.83; N, 2.04 Mol. Wt.: 706.35 -Preparation 11 Preparation of Compound 11:
6-~4-Methylbenzoyloxy)-2-[4-(4-methylbenzoyloxy)-phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone hydrochloride.
Compound 11 was prepared from the free base using a procedure similar to that of Preparation 2.
FDMS: m/e = 710 (M-HCl-l) Elemental Analysis of C44H40ClN06S:
Theor.: C, 70.81; H, 5.39; N, 1.88 Found: C, 71.10; H, 5.39; N, 1.94 Mol. Wt.: 746.33 Preparation 12 Preparation of Compound 12:
6-Benzoyloxy-2-[4-benzoyloxy)phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
Compound 12 was prepared from the appropriate acid chloride as described in Preparation 1.
FDMS: m/e = 682 (M+l) 2 1~
Elemental Analysis of C42H3sN06S:
Calc: C, 73.80; H, 5.14; N, 2.05 Eound: C, 73.27; H, 5.27; N, 1.94 Mol. Wt.: 681.8 Preparation 13 Preparation of Compound 13:
6-(n-Butoxyoyloxy)-2-[4(n-butoxyoyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
Compound 13 was prepared in a manner analogousto that described in Preparation 1, except that n-butylchloroformate was used in place of the acid chloride.
Yield = 6.13 g in form of oil.
PMR: consistent with structure FDMS: m/e = 674 (M+l) ' 6 -x-7947 -32-Preparation 14 Preparation of Compound 14:
6-(n-sutoxycarbonyloxy)-2-[4~n-butoxycarbonyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone hydrochloride.
Compound 13 was converted to the hydrochloride salt in a manner analogous to that described in Preparation 6.
PMR: consistent with structure Elemental Analysis of C3gH44ClNOgS:
Calc: C, 64.26; H, 6.24; N, 1.97 Found: C, 63.97; H, 6.34; N, 1.98 Mol. Wt.: 710.29 Preparation 15 Preparation of Compound 15:
6-(Phenyloxycarbonyloxy)-2-[4(phenyloxycarbonyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone.
This compound was prepared in a manner analogous to that described in Preparation 13, but using the 2 1 ~
appropriate acyl ester. Yield = 3.59 g of final product as a tan amorphous powder.
PMR: consistent with structure FDMS: m/e = 713 (M+) Pre~aration 16 Preparation of Compound 16:
6-(Phenyloxycarbonyloxy)-2-[4(phenyloxycarbonyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone hydrochloride.
Compound 15 was converted to the hydrochloride salt in a manner analogous to that described in Preparation 6.
PMR: consistent with structure Elemental Analysis of C3gH44ClNOgS:
Calc: C, 67.24; H, 4.84; N, 1.87 Found: C, 66.94; H, 4.96; N, 1.84 Mol. Wt.: 750.27 9~
Preparation 17 Preparation of Compound 17:
6-(Naphthoyloxy)-2-[4(1-naphthoyloxy)phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone.
Compound 17 was prepared as described in Preparation 1 using the appropriate acid halide. Yield =
3.5 g of a white amorphous powder PMR: consistent with structure FDMS: m/e = 781 (M+) Elemental Analysis of CsoH3gN06S:
Calc: C, 76.80; H, 5.03; N, 1.79 Found: C, 76.53; ~, 5.20; N, 1.53 Mol. Wt.: 781.94 Preparation 18 Preparation of Compound 18:
6-(Methoxyethanoyloxy)-2-[4(methoxyethanoyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone.
Compound 18 was prepared as described in Preparation 1 using the appropriate acid halide. Yield =
3.61 g of a gummy solid.
PMR: consistent with structure FDMS: m/e = 618 (M+l) Pre~aration 19 Preparation of Compound 19:
6-(Methoxyethanoyloxy)-2-[4(methoxyethanoyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone hydrochloride.
Compound 19 was prepared from 3.5 g of Compound 18 as described in Preparation 2. Yield = 1.65 g of amorphous white powder.
PMR: consistent with structure FDMS: m/e = 618 (M+l) Elemental AnalySis of C34H36N08S:
Calc: C, 62.43; H, 5.55; N, 2.14 Found: C, 62.23; H, 5.63; N, 2.15 The following nonlimiting examples illustrate the methods and formulations of this invention.
x-7947 -36-Exam~le 1 In the examples illustrating the methods, a model of post-menopausal osteoporosis was used in which effects of different treatments upon femur density were determined.
Seventy-five day old female Sprague Dawley rats (weight range of 225 to 275 g) were obtained from Charles River Laboratories (Portage, MI). They were housed in groups of 3 and had ad libi tum access to food (calcium content approximately 1%) and water. Room temperature was maintained at 22.2~ i 1.7~ C with a minimum relative humidity of 40%. The photoperiod in the room was 12 hours light and 12 hours dark.
One week after arrival, the rats underwent bilateral ovariectomy under anesthesia (44 mg/kg Ketamine and 5 mg/kg Xylazine (sutler, Indianapolis, IN) administered intramuscularly). Treatment with vehicle, estrogen, or a compound of formula I was initiated on the day of surgery following recovery from anesthesia. Oral dosage was by gavage in 0.5 mL of 1% carboxymethylcellulose (CMC). Body weight was determined at the time of surgery and weekly thereafter and the dosage was adjusted with changes in body weight. Vehicle or estrogen treated ovariectomized (ovex) rats and non-ovariectomized (intact) rats were evaluated in parallel with each experimental group to serve as negative and positive controls.
i 6 The rats were treated daily for 35 days (6 rats per treatment group) and sacrificed by decapitation on the 36th day. The 35 day time period was sufficient to allow maximal reduction in bone density, measured as described herein. At the time of sacrifice, the uteri were removed, dissected free of extraneous tissue, and the fluid contents were expelled before determination of wet weight in order to confirm estrogen deficiency associated with complete ovariectomy. Uterine weight was routinely reduced about 75% in response to ovariectomy. The uteri were then placed in 10% neutral buffered formalin to allow for subsequent histological analysis.
The right femurs were excised and scanned at the distal metaphysis 1 mm from the patellar groove with single photon absorptiometry. Results of the densitometer measurements represent a calculation of bone density as a function of the bone mineral content and bone width.
INFLUENCE OF RALOXIFENE ON BONE DENSITY
The results of control treatments from five separate experiments are accumulated in Table 2. In summary, ovariectomy of the rats caused a reduction in femur density of about 25% as compared to intact vehicle treated controls. Estrogen, administered in the orally active form of ethynyl estradiol (EE2), prevented this loss of bone in a dose dependent manner, but it also exerted a 2~~3~
-stimulatory action on the uterus resulting in uterine weights approaching that of an intact rat when administered at 100 ~g/kg. Results are reported as the mean of measurements from thirty rats + the standard error of the mean.
In these studies raloxifene, administered as the hydrochloride, also prevented bone loss in a dose dependent manner; however, only minimal increase of uterine weight over the ovariectomized controls was present in these animals. The results of five assays using raloxifene are combined in Table 3. Accordingly, each point reflects the responses of thirty rats and depicts a typical dose response curve for raloxifene in this model. Results are reported as the mean + the standard error of the mean.
' -Bone DensityUterine Weight (mg/cm/cm) (mg) Ovariectomy control 170 + 3 127 i 5 (0.5 mL CMC oral) Intact control 220 + 4 545 + 19 (0.5 mL CMC oral) EE2 100 ~g/kg, oral 210 + 4 490 + 11 TAsLE 3 Bone Den~ity Uterine Weight (mg/cm/cm) (mg) Ovariectomy control171 + 3 127 + 5 (0.5 mL CMC oral) Intact control 222 + 3 540 + 22 (0.5 mL CMC oral) raloxifene 0.01 mg/kg, oral 176 + 3 150 + 5 raloxifene 0.10 mg/kg, oral 197 + 3 196 + 5 raloxifene 1.00 mg/kg, oral 201 + 3 199 + 5 raloxifene 10.00 mg/kg, oral 199 + 3 186 + 4 Exam~le 2 Raloxifene, as the hydrochloride, was administered alone or in combination with ethynyl estradiol. Rats treated with raloxifene alone had uterine weights which were marginally higher than the ovariectomized controls and much less than those of ethynyl estradiol treated rats, which approached those of the intact controls. Conversely, raloxifene treatment significantly reduced bone loss in ovariectomized rats, and when given in combination with ethynyl estradiol it did not 2i~?~3~' appreciably reduce the protective effect of the estrogen on bone density. The results are shown in Table 4.
TAsLE 4 Bone Density Uterine Weight Experiment A (mg/cm/cm) (mg) Ovariectomy control162 _ 4 142 + 18 (0.5 mL CMC oral) Intact control 219 _ 5 532 + 49 (0.5 mL CMC oral) EE2 100 ~g/kg, oral202 _ 6 450 17 EE2 100 ~g/kg + 204 + 2 315 + 10 raloxifene 0.10 mg/kg, oral EE2 100 ~g/kg + 200 + 5 250 + 21 raloxifene 1 mg/kg, oral Bone Density Uterine Weight Experiment B (mg/cm/cm) (mg) Ovariectomy control165 _ 8 116 _ 6 (0.5 mL CMC oral) Intact control 220 _ 4 605 + 69 (0.5 mL CMC oral) EE2 100 ~g/kg, oral215 _ 11481 i 24 raloxifene 1 mg/kg +197 + 7263 + 17 EE2 100 ~g/kg, oral raloxifene 1 mg/kg198 _ 11 202 + 5 Exam~le 3 The ability of raloxifene to inhibit bone loss was compared to that of tamoxifen (SIGMA, St. Louis, Mo).
Tamoxifen, a well known antiestrogen currently used in the treatment of certain cancers, has been shown to inhibit bone loss (see for example, Love, R., et al. 1992 "Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer", N Eng J Med 326:852; Turner, R., et al. 1988 ~'Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats'~, Endo 122:1146). A relatively narrow range of doses of raloxifene and tamoxifen was administered orally to ovariectomized rats as in the previous example. Although both of these agents displayed the ability to prevent reduction of femur density while evoking only modest uterotrophic activity, as identified by gains in uterine weight (Table 5), a comparison of several histological parameters demonstrated a marked difference between the rats treated with these agents (Table 6).
Increases in epithelial height are a sign of estrogenicity of therapeutic agents and may be associated with increased incidence of uterine cancer. When raloxifene was administered as described in Example 1, only at one dose was there any statistically measurable increase in epithelial height over the ovariectomized controls.
This was in contrast to the results seen with tamoxifen and estrogen. At all doses given, tamoxifen increased epithelial height equal to that of an intact rat, about a six-fold increase over the response seen with raloxifene.
Estradiol treatment increased epithelial height to a thickness greater than intact rats.
Estrogenicity was also assessed by evaluating the adverse response of eosinophil infiltration into the 3 5 ~
stromal layer of the uterus (Table 6). Raloxifene did not cause any increase in the number of eosinophils observed in the stromal layer of ovariectomized rats while tamoxifen caused a significant increase in the response. Estradiol, as expected, caused a large increase in eosinophil infiltration.
Little or no difference was detectable between raloxifene and tamoxifen effects on thickness of the stroma and myometrium. Both agents caused an increase in these measurements that was much less than the effect of estrogen.
A total score of estrogenicity, which was a compilation of all four parameters, showed that raloxifene was significantly less estrogenic than tamoxifen.
Bone Den~ity Uterine Weight (mg/cm/cm) (mg) Ovariectomy control 171 + 5 126 + 17 (0.5 mL CMC oral) - -Intact control 208 + 4 490 + 6 (0.5 mL CMC oral) - -EE2 100 ~g/kg, oral 212 _ 10 501 _ 37 raloxifene 1 mg/kg, oral 207 + 13 198 _ 9 tamoxifen 1 mg/kg, oral 204 _ 7 216 _ 18 X-7947 _43~ fi Epitheli A 1 Stromal Mycmetrial St ~ -~eiqht ~o~int~phjl~ Thickn~s ~-p~n~i Ovariectomy control 1.24 1.00 4.42 10.83 (0.5 mL CMC oral) 2.71 4.17 8.67 20.67 EE2 100 ~g/kg, oral 3.42 5.17 8.92 21.17 raloxifene 1 mg/kg 1.67 1.17 5.42 14.00 t: -- fen 1 mg/kg 2.58 2.83 5.50 14.17 Example 4 Other compounds of formula I were administered orally in the rat assay described in Example 1. Table 7 reports the effect of a 1 mg/kg dose of each compound in terms of a percent inhibition of bone loss and percent uterine weight gain.
TAsLE 7 Compound ~ Inhibition ~ Uterine Numberof Bone LossaWeight Gainb a 86 26 a Percent inhibition of bone loss = (bone density of treated ovex animals - bone density of untreated ovex animals) + (bone density of estrogen treated ovex animals - bone density of untreated ovex animals) x 100.
b Percent uterine weight gain = (uterine weight of treated ovex animals - uterine weight of ovex animals) + (uterine weight of estrogen treated ovex animals - uterine weight of ovex animals) x 100 .
210135 ~
-Example 5 Fracture rate as a consequence of osteoporosis is inversely correlated with bone mineral density.
However, changes in bone density occur slowly, and are measured meaningfully only over many months or years. It is possible, however, to demonstrate that the formula I
compounds, such as raloxifene, have positive effects on bone mineral density and bone loss by measuring various quickly responding biochemical parameters that reflect changes in skeletal metabolism. To this end, in a current test study of raloxifene (administered as the hydrochloride) at least one hundred-sixty patients are enrolled and randomized to four treatment groups:
estrogen, two different doses of raloxifene, and placebo.
Patients are treated daily for eight weeks.
Blood and urine are collected before, during, and at the conclusion of treatment. In addition, an assessment of the uterine epithelium is made at the beginning and at the conclusion of the study. Estrogen administration and placebo serve as the positive and negative controls, respectively.
The patients are healthy post-menopausal (surgical or natural) women, age 45-60 who would normally be considered candidates for estrogen replacement in treatment for osteoporosis. This includes women with an ~ ~G~
intact uterus, who have had a last menstrual period more than six months, but less than six years in the past.
Patients who have received any of the following medications systematically at the beginning of the study are excluded from the study: vitamin D, corticosteroids, hypolipidemics, thiazides, antigout agents, salicylates, phenothiazines, sulfonates, tetracyclines, neomycin, and antihelmintics. Patients who have received any estrogen, progestin, or androgen treatment more recently than three months prior to the beginning of the study; patients who have ever received calcitonin, fluoride, or bisphosphonate therapy; patients who have diabetes mellitus; patients who have a cancer history anytime within the previous five years; patients with any undiagnosed or abnormal genital bleeding; patients with active, or a history of, thromboembolic disorders; patients who have impaired liver or kidney function; patients who have abnormal thyroid function; patients who are poor medical or psychiatric risks; or patients who consume an excess of alcohol or abuse drugs.
Patients in the estrogen treatment group receive 0.625 mg/day and the two raloxifene groups receive dosages of 200 and 600 mg/day, all groups receiving oral capsule formulations. Calcium carbonate, 648 mg tablets, is used as calcium supplement with all patients taking 2 tablets each morning during the course of the study.
21fli~
x-7947 -47-The study is a double-blind design. The investigators and the patients do not know the treatment group to which the patient is assigned.
A baseline examination of each patient includes quantitative measurement of urinary calcium, creatinine, hydroxyproline, and pyridinoline crosslinks. Blood samples are measured for serum levels of osteocalcin, bone-specific alkaline phosphatase, raloxifene, and raloxifene metabolites. saseline measurements also include e~min~tion of the uterus including uterine biopsy.
During subsequent visits to the investigating physician, measurements of the above parameters in response to treatment are repeated. The biochemical markers listed above that are associated with bone resorption have all been shown to be inhibited by the administration of estrogen as compared to an untreated individual.
Raloxifene is also expected to inhibit the markers in estrogen deficient individuals as an indication that raloxifene is effective in inhibiting bone loss from the time that treatment is begun.
Subsequent longer term studies can incorporate the direct measurement of bone density by the use of a photon absorptiometry and the measurement of fracture rates associated with therapy.
IngredientQuantity (mg/capsule) Active ingredient 0.1 - 1000 Starch, NF 0 - 650 Starch flowable powder0 - 650 Silicone fluid 350 centistokes 0 - 15 The ingredients are blended, passed through a ~o. 45 mesh u.S. sieve, and filled into hard gelatin capsules.
Examples of specific capsule formulations containing raloxifene, as the hydrochloride salt, that have been made include those shown below:
Formulation 2: Raloxifene capsule IngredientQuantity (mg/capsule) Raloxifene hydrochloride Starch, NF 112 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 3: Raloxifene capsule IngredientQuantity (mg/capsule) Raloxifene hydrochloride 5 Starch, NF 108 Starch flowable powder 225.3 Silicone fluid 350 centistokes 1.7 Formulation 4: Raloxifene capsule IngredientQuantity (mg/capsule) Raloxifene hydrochloride 10 Starch, NF 103 Starch flowable powder225.3 Silicone fluid 350 centistokes 1.7 Formulation 5: Raloxifene capsule Ingredient Quantity (mg/capsule) Raloxifene hydrochloride 50 Starch, NF 150 Starch flowable powder 397 Silicone fluid 350 centistokes 3.0 The specific formulations above may be changed in compliance with the reasonable variations provided.
A tablet formulation is prepared using the ingredients below:
Formulation 6: Tablets Ingredient Quantity (~.g/tablet) Active ingredient 0.1 - lO00 Cellulose, microcrystalline0 - 650 Silicon dioxide, fumed 0 - 650 Stearic ac~d 0 - 15 The components are blended and compressed to form tablets.
, I
.. ~, ~3~
x-7947 -19-Alternatively, tablets each containing 0.1 -1000 mg of active ingredient are made up as follows:
Formulation 7: Tablets Ingredient Quantity (mg/tablet) Active in~redient 0.1 - 1000 Starch 45 Cellulose, microcrystalline 35 Polyvinylpyrrolidone 4 (as 10% solution in water) Sodium carboxymethyl cellulose 4.5 Magnesium stearate 0.5 Talc The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50~-60~ C and passed through a No. 18 mesh U.S. sieve.
The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 60 U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets.
Suspensions each containing 0.1 - 1000 mg of medicament per 5 mL dose are made as follows:
Formulation 8: Suspensions Ingredient Quantity (mg/5 ml) Active ingredient 0.1 - 1000 mg Sodium carboxymethyl cellulose 50 mg Syrup 1.25 mg Benzoic acid solution 0.10 mL
Flavor q.v.
Color q.v.
Purified water to 5 mL
The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor, and color are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
Illustrative compounds that can be used in the formulations and methods of this invention are shown in Table 1.
2 i ~ 6 _ Tabl e Compound No. n R and Rl R2 Form 1 0-OC(O) ~ F piperidino base 2 0-OC(O) ~ F piperidino HCl 3 o-OC(O) ~ piperidino base 4 0-OC(O) ~ piperidino HCl o. -OC(O)CH2CH2CH3 piperidino base 6 0-OC(O)CH2CH2CH3 piperidino HCl 7 o-OC(O)C(CH3)3 piperidino base 8 0-oc(o)C(CH3)3 piperidino HCl 9 0-OC(O)CH2C(CH3)3 piperidino base 0-Oc(O)CH2C(CH3)3 piperidino HCl 11 0-OC(O) ~ CH3 piperidino HCl 12 0-OC(O) ~ piperidino base 13 0-oc(o)ocH2cH2cH2cH3 piperidino base 14 0-OC(O)OCH2CH2CH2CH3 piperidino HCl 0-OC(O)O ~ piperidino base 16 0-OC(O)O ~ piperidino HCl 17 0-OC(O) ~ piperidino base 18 0-OC(O)CH2CH20CH3 piperidino base 19 0-OC(O)CH2CH20CH3 piperidino HCl 0 OH piperidino base 3 ~ ~
-Table 1 (cont. ) Compound No. n R and R1 R2 Form 21 0 OH piperidino HC1 22 0 H piperidino base 23 1 OH piperidino HCl 24 2 OH piperidino HC1 1 H piperidino HC1 26 0 OH pyrrolidino base 27 0 o~ pyrrolidino HC1 28 1 OH pyrrolidino HC1 29 2 OH pyrrolidino HC1 0 H pyrrolidino HC1 31 0 OH hexamethyleneimino HC1 32 1 OH hexamethyleneimino HCl 33 2 OH hexamethyleneimino HCl 34 0 OCH3 piperidino HCl -In the following Preparations, the compound numbers correspond to those given in Table 1 Pre~aration 1 Preparation of Compound 1:
6-(4-Fluorobenzoyloxy)-2-[4-(4-fluorobenzoyloxy)phenyl]-benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone.
Raloxifene hydrochloride (also called, 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-l-yl)ethoxyphenyl]-methanone hydrochloride), (5.1 g, 10 mmol) was suspended in 250 mL of dry tetrahydrofuran (THF) and 7.1 g (70 mmol) of triethylamine, and approximately 10 mg of 4-(N,N-dimethylamino)pyridine were added. The suspension was cooled in an ice bath and placed under an atmosphere of nitrogen. 4-Fluorobenzoyl chloride (4.75 g, 30 mmol), dissolved in 20 mL of dry THF, was slowly added over a twenty minute period. The reaction mixture was stirred and allowed to slowly warm to room temperature over a period of eighteen hours. It was then filtered, and the filtrate was evaporated to a gum in vacuo. The crude product thus obtained was dissolved in a small volume of chloroform and chromatographed (HPLC) on a silica gel column eluted with a linear gradient of solvent, starting with chloroform and ending with a mixture of ~1û13~
.
chloroform-methanol (19:1 (v/v)). The fractions containing the desired product as determined by thin layer chromatography (silica, chloroform-methanol (9:1)) were combined and evaporated to a gum. The final product was crystallized from ether to give 3.21 g of compound 1.
PMR: consistent with the structure FDMS: m/e - 717 M+
Elemental Analysis for C42H33F2NO6S:
Theor: C, 70.29; H, 4.60; N, 1.95 Found: C, 70.05; H, 4.60; N, 1.89 Mol. wt.: 717 Pre~aration 2 Preparation of Compound 2:
6-(4-Fluorobenzoylo.Yy)-2-[4-(4-fluorobenzoyloxy)-phenyl]-benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]-phenyl]-methanone hydrochloride.
Compound 1 (5.15 g, 7.18 mmol) was dissolved in 25 mL THF, and 150 mL ether was added. Dry HCl gas was bubbled into the solution, and a white gummy precipitate formed. The liquid was removed by decanting, and the residue was crystallized from ethyl acetate with a small amount of ethanol added to effect solution. The product 2 ~
-was filtered, washed with ether, and dried to give 4.41 g of Compound 2 as a white powder.
PMR: consistent with the structure Elemental Analysis for C42H34clF2NO6s:
Theor: C, 66.88; H, 4.54; N, 1.86 Found: C, 66.59, H, 4.39; N, 1.60 Mol. Wt.: 753.5 Pre~aration 3 Preparation of Compound 3:
6-(Cyclopropylcarbonyloxy)-2-[4-(cyclopropylcarbonyloxy)-phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
The title compound was prepared using procedures analogous to those in Preparation 1, but using cyclopropylcarbonyl chloride, except that the product was not crystallized. Yield = 2.27 g.
PMR: consistent with the structure FDMS: m/e = 610 M+
' -Preparation 4 Preparation of Compound 4:
6-(Cyclopropylcarbonyloxy)-2-[4-(cyclopropylcarbonyloxy)-phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone hydrochloride.
Compound 4 was prepared from Compound 3 as described in Preparation 2.
Preparation 5 Preparation of Compound 5: - .
6-(n-Butanoyloxy)-2-[4-(n-butanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone.
Compound 5 was prepared using the method of Preparation 1, but starting with n-butanoyl chloride, to give 4.12 g of final product as an oil.
PMR. consistent with the structure FDMS: m/e = 614 (M+l) 2 1 ~
._ x-7947 -27-Pre~aration 6 Preparation of Compound 6:
6-(n-Butanoyloxy)-2-[4-(n-butanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride.
Compound 5 (4.12 g) was dissolved in ethyl acetate (50 mL), and a solution of HCl in ether was added until the precipitation stopped. The liquid was decanted off, and the white, gummy residue was triturated with diethyl ether and filtered. The residue was dried to give 1.33 g of Compound 6.
PMR: consistent with the structure Elemental Analysis of for C36H40ClNO6S:
Theor.: C, 66.50; H, 6.20; N, 2.15 Found: C, 66.30; H, 6.28; N, 1.98 Mol. Wt.: 650.24 3 ~ ~
Preparation 7 Preparation of Compound 7:
6-(2,2-Dimethylpropanoyloxy~-2-[4-(2,2-dimethyl-propanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone.
Compound 7 was prepared using the procedure of Preparation 1, but using 2,2-dimethylpropanoyl chloride.
Preparation 8 Preparation of Compound 8:
6-(2,2-Dimethylpropanoyloxy)-2-[4-(2,2-dimethyl-propanoyloxy)phenyl]benzo[b]thien-3-yl-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride.
Compound 8 was prepared from Compound 7, as described in Preparation 2.
FDMS: m/e = 641 (M-HCl-l) Elemental Analysis of C3gH44ClN06S:
Theor.: C, 67.29; H, 6.54i N, 2.07 Found: C, 67.02; H, 6.54; N, 1.90 Mol. Wt.: 678.29 21Ql~
Preparation 9 Preparation of Compound 9:
6-(3,3-Dimethylbutanoyloxy)-2-[4-(3,3-dimethylbutanoyloxy)-phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
Compound 9 was prepared using the procedures of Preparation 1, but with 3,3-dimethylbutanoyl chloride.
Pre~aration 10 Preparation of Compound 10:
6-(3,3-Dimethylbutanoyloxy)-2-[4-(3,3-dimethylbutanoyloxy)-phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone hydrochloride.
Compound 10 was prepared from Compound 9 as described in Preparation 2.
FDMS: m/e = 669 (M-HCl-l) Elemental Analysis of C40H4gClN06S:
Theor.: C, 68.02; H, 6.85; N, 1.98 Found: C, 67.75; H, 6.83; N, 2.04 Mol. Wt.: 706.35 -Preparation 11 Preparation of Compound 11:
6-~4-Methylbenzoyloxy)-2-[4-(4-methylbenzoyloxy)-phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone hydrochloride.
Compound 11 was prepared from the free base using a procedure similar to that of Preparation 2.
FDMS: m/e = 710 (M-HCl-l) Elemental Analysis of C44H40ClN06S:
Theor.: C, 70.81; H, 5.39; N, 1.88 Found: C, 71.10; H, 5.39; N, 1.94 Mol. Wt.: 746.33 Preparation 12 Preparation of Compound 12:
6-Benzoyloxy-2-[4-benzoyloxy)phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
Compound 12 was prepared from the appropriate acid chloride as described in Preparation 1.
FDMS: m/e = 682 (M+l) 2 1~
Elemental Analysis of C42H3sN06S:
Calc: C, 73.80; H, 5.14; N, 2.05 Eound: C, 73.27; H, 5.27; N, 1.94 Mol. Wt.: 681.8 Preparation 13 Preparation of Compound 13:
6-(n-Butoxyoyloxy)-2-[4(n-butoxyoyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]-phenyl]methanone.
Compound 13 was prepared in a manner analogousto that described in Preparation 1, except that n-butylchloroformate was used in place of the acid chloride.
Yield = 6.13 g in form of oil.
PMR: consistent with structure FDMS: m/e = 674 (M+l) ' 6 -x-7947 -32-Preparation 14 Preparation of Compound 14:
6-(n-sutoxycarbonyloxy)-2-[4~n-butoxycarbonyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone hydrochloride.
Compound 13 was converted to the hydrochloride salt in a manner analogous to that described in Preparation 6.
PMR: consistent with structure Elemental Analysis of C3gH44ClNOgS:
Calc: C, 64.26; H, 6.24; N, 1.97 Found: C, 63.97; H, 6.34; N, 1.98 Mol. Wt.: 710.29 Preparation 15 Preparation of Compound 15:
6-(Phenyloxycarbonyloxy)-2-[4(phenyloxycarbonyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone.
This compound was prepared in a manner analogous to that described in Preparation 13, but using the 2 1 ~
appropriate acyl ester. Yield = 3.59 g of final product as a tan amorphous powder.
PMR: consistent with structure FDMS: m/e = 713 (M+) Pre~aration 16 Preparation of Compound 16:
6-(Phenyloxycarbonyloxy)-2-[4(phenyloxycarbonyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone hydrochloride.
Compound 15 was converted to the hydrochloride salt in a manner analogous to that described in Preparation 6.
PMR: consistent with structure Elemental Analysis of C3gH44ClNOgS:
Calc: C, 67.24; H, 4.84; N, 1.87 Found: C, 66.94; H, 4.96; N, 1.84 Mol. Wt.: 750.27 9~
Preparation 17 Preparation of Compound 17:
6-(Naphthoyloxy)-2-[4(1-naphthoyloxy)phenyl]benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone.
Compound 17 was prepared as described in Preparation 1 using the appropriate acid halide. Yield =
3.5 g of a white amorphous powder PMR: consistent with structure FDMS: m/e = 781 (M+) Elemental Analysis of CsoH3gN06S:
Calc: C, 76.80; H, 5.03; N, 1.79 Found: C, 76.53; ~, 5.20; N, 1.53 Mol. Wt.: 781.94 Preparation 18 Preparation of Compound 18:
6-(Methoxyethanoyloxy)-2-[4(methoxyethanoyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone.
Compound 18 was prepared as described in Preparation 1 using the appropriate acid halide. Yield =
3.61 g of a gummy solid.
PMR: consistent with structure FDMS: m/e = 618 (M+l) Pre~aration 19 Preparation of Compound 19:
6-(Methoxyethanoyloxy)-2-[4(methoxyethanoyloxy)phenyl]-benzo[b]thien-3-yl[4-[2-(piperidin-1-yl)ethoxy]phenyl]-methanone hydrochloride.
Compound 19 was prepared from 3.5 g of Compound 18 as described in Preparation 2. Yield = 1.65 g of amorphous white powder.
PMR: consistent with structure FDMS: m/e = 618 (M+l) Elemental AnalySis of C34H36N08S:
Calc: C, 62.43; H, 5.55; N, 2.14 Found: C, 62.23; H, 5.63; N, 2.15 The following nonlimiting examples illustrate the methods and formulations of this invention.
x-7947 -36-Exam~le 1 In the examples illustrating the methods, a model of post-menopausal osteoporosis was used in which effects of different treatments upon femur density were determined.
Seventy-five day old female Sprague Dawley rats (weight range of 225 to 275 g) were obtained from Charles River Laboratories (Portage, MI). They were housed in groups of 3 and had ad libi tum access to food (calcium content approximately 1%) and water. Room temperature was maintained at 22.2~ i 1.7~ C with a minimum relative humidity of 40%. The photoperiod in the room was 12 hours light and 12 hours dark.
One week after arrival, the rats underwent bilateral ovariectomy under anesthesia (44 mg/kg Ketamine and 5 mg/kg Xylazine (sutler, Indianapolis, IN) administered intramuscularly). Treatment with vehicle, estrogen, or a compound of formula I was initiated on the day of surgery following recovery from anesthesia. Oral dosage was by gavage in 0.5 mL of 1% carboxymethylcellulose (CMC). Body weight was determined at the time of surgery and weekly thereafter and the dosage was adjusted with changes in body weight. Vehicle or estrogen treated ovariectomized (ovex) rats and non-ovariectomized (intact) rats were evaluated in parallel with each experimental group to serve as negative and positive controls.
i 6 The rats were treated daily for 35 days (6 rats per treatment group) and sacrificed by decapitation on the 36th day. The 35 day time period was sufficient to allow maximal reduction in bone density, measured as described herein. At the time of sacrifice, the uteri were removed, dissected free of extraneous tissue, and the fluid contents were expelled before determination of wet weight in order to confirm estrogen deficiency associated with complete ovariectomy. Uterine weight was routinely reduced about 75% in response to ovariectomy. The uteri were then placed in 10% neutral buffered formalin to allow for subsequent histological analysis.
The right femurs were excised and scanned at the distal metaphysis 1 mm from the patellar groove with single photon absorptiometry. Results of the densitometer measurements represent a calculation of bone density as a function of the bone mineral content and bone width.
INFLUENCE OF RALOXIFENE ON BONE DENSITY
The results of control treatments from five separate experiments are accumulated in Table 2. In summary, ovariectomy of the rats caused a reduction in femur density of about 25% as compared to intact vehicle treated controls. Estrogen, administered in the orally active form of ethynyl estradiol (EE2), prevented this loss of bone in a dose dependent manner, but it also exerted a 2~~3~
-stimulatory action on the uterus resulting in uterine weights approaching that of an intact rat when administered at 100 ~g/kg. Results are reported as the mean of measurements from thirty rats + the standard error of the mean.
In these studies raloxifene, administered as the hydrochloride, also prevented bone loss in a dose dependent manner; however, only minimal increase of uterine weight over the ovariectomized controls was present in these animals. The results of five assays using raloxifene are combined in Table 3. Accordingly, each point reflects the responses of thirty rats and depicts a typical dose response curve for raloxifene in this model. Results are reported as the mean + the standard error of the mean.
' -Bone DensityUterine Weight (mg/cm/cm) (mg) Ovariectomy control 170 + 3 127 i 5 (0.5 mL CMC oral) Intact control 220 + 4 545 + 19 (0.5 mL CMC oral) EE2 100 ~g/kg, oral 210 + 4 490 + 11 TAsLE 3 Bone Den~ity Uterine Weight (mg/cm/cm) (mg) Ovariectomy control171 + 3 127 + 5 (0.5 mL CMC oral) Intact control 222 + 3 540 + 22 (0.5 mL CMC oral) raloxifene 0.01 mg/kg, oral 176 + 3 150 + 5 raloxifene 0.10 mg/kg, oral 197 + 3 196 + 5 raloxifene 1.00 mg/kg, oral 201 + 3 199 + 5 raloxifene 10.00 mg/kg, oral 199 + 3 186 + 4 Exam~le 2 Raloxifene, as the hydrochloride, was administered alone or in combination with ethynyl estradiol. Rats treated with raloxifene alone had uterine weights which were marginally higher than the ovariectomized controls and much less than those of ethynyl estradiol treated rats, which approached those of the intact controls. Conversely, raloxifene treatment significantly reduced bone loss in ovariectomized rats, and when given in combination with ethynyl estradiol it did not 2i~?~3~' appreciably reduce the protective effect of the estrogen on bone density. The results are shown in Table 4.
TAsLE 4 Bone Density Uterine Weight Experiment A (mg/cm/cm) (mg) Ovariectomy control162 _ 4 142 + 18 (0.5 mL CMC oral) Intact control 219 _ 5 532 + 49 (0.5 mL CMC oral) EE2 100 ~g/kg, oral202 _ 6 450 17 EE2 100 ~g/kg + 204 + 2 315 + 10 raloxifene 0.10 mg/kg, oral EE2 100 ~g/kg + 200 + 5 250 + 21 raloxifene 1 mg/kg, oral Bone Density Uterine Weight Experiment B (mg/cm/cm) (mg) Ovariectomy control165 _ 8 116 _ 6 (0.5 mL CMC oral) Intact control 220 _ 4 605 + 69 (0.5 mL CMC oral) EE2 100 ~g/kg, oral215 _ 11481 i 24 raloxifene 1 mg/kg +197 + 7263 + 17 EE2 100 ~g/kg, oral raloxifene 1 mg/kg198 _ 11 202 + 5 Exam~le 3 The ability of raloxifene to inhibit bone loss was compared to that of tamoxifen (SIGMA, St. Louis, Mo).
Tamoxifen, a well known antiestrogen currently used in the treatment of certain cancers, has been shown to inhibit bone loss (see for example, Love, R., et al. 1992 "Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer", N Eng J Med 326:852; Turner, R., et al. 1988 ~'Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats'~, Endo 122:1146). A relatively narrow range of doses of raloxifene and tamoxifen was administered orally to ovariectomized rats as in the previous example. Although both of these agents displayed the ability to prevent reduction of femur density while evoking only modest uterotrophic activity, as identified by gains in uterine weight (Table 5), a comparison of several histological parameters demonstrated a marked difference between the rats treated with these agents (Table 6).
Increases in epithelial height are a sign of estrogenicity of therapeutic agents and may be associated with increased incidence of uterine cancer. When raloxifene was administered as described in Example 1, only at one dose was there any statistically measurable increase in epithelial height over the ovariectomized controls.
This was in contrast to the results seen with tamoxifen and estrogen. At all doses given, tamoxifen increased epithelial height equal to that of an intact rat, about a six-fold increase over the response seen with raloxifene.
Estradiol treatment increased epithelial height to a thickness greater than intact rats.
Estrogenicity was also assessed by evaluating the adverse response of eosinophil infiltration into the 3 5 ~
stromal layer of the uterus (Table 6). Raloxifene did not cause any increase in the number of eosinophils observed in the stromal layer of ovariectomized rats while tamoxifen caused a significant increase in the response. Estradiol, as expected, caused a large increase in eosinophil infiltration.
Little or no difference was detectable between raloxifene and tamoxifen effects on thickness of the stroma and myometrium. Both agents caused an increase in these measurements that was much less than the effect of estrogen.
A total score of estrogenicity, which was a compilation of all four parameters, showed that raloxifene was significantly less estrogenic than tamoxifen.
Bone Den~ity Uterine Weight (mg/cm/cm) (mg) Ovariectomy control 171 + 5 126 + 17 (0.5 mL CMC oral) - -Intact control 208 + 4 490 + 6 (0.5 mL CMC oral) - -EE2 100 ~g/kg, oral 212 _ 10 501 _ 37 raloxifene 1 mg/kg, oral 207 + 13 198 _ 9 tamoxifen 1 mg/kg, oral 204 _ 7 216 _ 18 X-7947 _43~ fi Epitheli A 1 Stromal Mycmetrial St ~ -~eiqht ~o~int~phjl~ Thickn~s ~-p~n~i Ovariectomy control 1.24 1.00 4.42 10.83 (0.5 mL CMC oral) 2.71 4.17 8.67 20.67 EE2 100 ~g/kg, oral 3.42 5.17 8.92 21.17 raloxifene 1 mg/kg 1.67 1.17 5.42 14.00 t: -- fen 1 mg/kg 2.58 2.83 5.50 14.17 Example 4 Other compounds of formula I were administered orally in the rat assay described in Example 1. Table 7 reports the effect of a 1 mg/kg dose of each compound in terms of a percent inhibition of bone loss and percent uterine weight gain.
TAsLE 7 Compound ~ Inhibition ~ Uterine Numberof Bone LossaWeight Gainb a 86 26 a Percent inhibition of bone loss = (bone density of treated ovex animals - bone density of untreated ovex animals) + (bone density of estrogen treated ovex animals - bone density of untreated ovex animals) x 100.
b Percent uterine weight gain = (uterine weight of treated ovex animals - uterine weight of ovex animals) + (uterine weight of estrogen treated ovex animals - uterine weight of ovex animals) x 100 .
210135 ~
-Example 5 Fracture rate as a consequence of osteoporosis is inversely correlated with bone mineral density.
However, changes in bone density occur slowly, and are measured meaningfully only over many months or years. It is possible, however, to demonstrate that the formula I
compounds, such as raloxifene, have positive effects on bone mineral density and bone loss by measuring various quickly responding biochemical parameters that reflect changes in skeletal metabolism. To this end, in a current test study of raloxifene (administered as the hydrochloride) at least one hundred-sixty patients are enrolled and randomized to four treatment groups:
estrogen, two different doses of raloxifene, and placebo.
Patients are treated daily for eight weeks.
Blood and urine are collected before, during, and at the conclusion of treatment. In addition, an assessment of the uterine epithelium is made at the beginning and at the conclusion of the study. Estrogen administration and placebo serve as the positive and negative controls, respectively.
The patients are healthy post-menopausal (surgical or natural) women, age 45-60 who would normally be considered candidates for estrogen replacement in treatment for osteoporosis. This includes women with an ~ ~G~
intact uterus, who have had a last menstrual period more than six months, but less than six years in the past.
Patients who have received any of the following medications systematically at the beginning of the study are excluded from the study: vitamin D, corticosteroids, hypolipidemics, thiazides, antigout agents, salicylates, phenothiazines, sulfonates, tetracyclines, neomycin, and antihelmintics. Patients who have received any estrogen, progestin, or androgen treatment more recently than three months prior to the beginning of the study; patients who have ever received calcitonin, fluoride, or bisphosphonate therapy; patients who have diabetes mellitus; patients who have a cancer history anytime within the previous five years; patients with any undiagnosed or abnormal genital bleeding; patients with active, or a history of, thromboembolic disorders; patients who have impaired liver or kidney function; patients who have abnormal thyroid function; patients who are poor medical or psychiatric risks; or patients who consume an excess of alcohol or abuse drugs.
Patients in the estrogen treatment group receive 0.625 mg/day and the two raloxifene groups receive dosages of 200 and 600 mg/day, all groups receiving oral capsule formulations. Calcium carbonate, 648 mg tablets, is used as calcium supplement with all patients taking 2 tablets each morning during the course of the study.
21fli~
x-7947 -47-The study is a double-blind design. The investigators and the patients do not know the treatment group to which the patient is assigned.
A baseline examination of each patient includes quantitative measurement of urinary calcium, creatinine, hydroxyproline, and pyridinoline crosslinks. Blood samples are measured for serum levels of osteocalcin, bone-specific alkaline phosphatase, raloxifene, and raloxifene metabolites. saseline measurements also include e~min~tion of the uterus including uterine biopsy.
During subsequent visits to the investigating physician, measurements of the above parameters in response to treatment are repeated. The biochemical markers listed above that are associated with bone resorption have all been shown to be inhibited by the administration of estrogen as compared to an untreated individual.
Raloxifene is also expected to inhibit the markers in estrogen deficient individuals as an indication that raloxifene is effective in inhibiting bone loss from the time that treatment is begun.
Subsequent longer term studies can incorporate the direct measurement of bone density by the use of a photon absorptiometry and the measurement of fracture rates associated with therapy.
Claims (17)
1. The use of a compound of formula (I):
wherein n is 0, 1 or 2;
R and R1, independently, are hydrogen, hydroxyl, C1-C6-alkoxyl, C1-C6-acyloxy, C1-C6-alkoxy-C2-C6-acyloxy, R3-substituted aryloxy, R3-substituted aroyloxy, R4-substituted carbonyloxy, chloro, or bromo;
R2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino;
R3 is C1-C3-alkyl, C1-C3-alkoxy, hydrogen, or halo;
and R4 is C1-C6-alkoxy or aryloxy; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament useful for treating or preventing osteoporosis in a human.
wherein n is 0, 1 or 2;
R and R1, independently, are hydrogen, hydroxyl, C1-C6-alkoxyl, C1-C6-acyloxy, C1-C6-alkoxy-C2-C6-acyloxy, R3-substituted aryloxy, R3-substituted aroyloxy, R4-substituted carbonyloxy, chloro, or bromo;
R2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino;
R3 is C1-C3-alkyl, C1-C3-alkoxy, hydrogen, or halo;
and R4 is C1-C6-alkoxy or aryloxy; or a pharmaceutically acceptable salt thereof, in the preparation of a medicament useful for treating or preventing osteoporosis in a human.
2. The use of raloxifene, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament useful for inhibiting bone loss in a human.
3. The use of raloxifene hydrochloride in the preparation of a medicament useful for inhibiting bone loss in a human.
4. The use of claim 2 or claim 3 for the preparation of a medicament useful for inhibiting bone loss in a human without the associated adverse effects of estrogen therapy.
5. The use of claim 4 wherein the medicament is useful in long-term treatment with diminished risk of developing the undesirable effects of customary estrogen replacement therapy.
6. The use of any one of claims 1 - 3 wherein the medicament is for use in combination with estrogen.
7. The use of any one of claims 1 to 3 wherein the medicament is for the treatment of a human diagnosed as suffering from osteoporosis.
8. The use of any one of claims 1 to 3 wherein the medicament is for prophylactic administration.
9. The use of any one of claims 1 - 3 wherein the medicament is for a treatment carried out from 1 to 3 times per day.
10. The use of claim 9 wherein the dosage of the medicament is from 0.1 to 1000 mg.
11. The use of claim 10 wherein the dosage of the medicament is from 50 to 400 mg.
12. The use of claim 11 wherein the dosage of the medicament is from 50 to 200 mg.
13. The use of any one of claims 1 - 3 wherein the medicament is suitable for use by the oral route.
14. The use of any one of claims 1 - 3 wherein the medicament is for the treatment of an aging human.
15. The use of claim 14 wherein the medicament is for the treatment of a post-menopausal female.
16. The use of any one of claims 1 to 3 wherein the medicament is for the treatment of a male showing evidence of bone loss.
17. The use of any one of claims 1 - 3 wherein the medicament is for the treatment of a patient without eliciting significant estrogenic responses in the primary sex tissues.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92093392A | 1992-07-28 | 1992-07-28 | |
US07/920,933 | 1992-07-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2101356A1 CA2101356A1 (en) | 1994-01-29 |
CA2101356C true CA2101356C (en) | 1998-11-17 |
Family
ID=25444642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002101356A Expired - Lifetime CA2101356C (en) | 1992-07-28 | 1993-07-27 | Improvements in or relating to benzothiophenes |
Country Status (35)
Country | Link |
---|---|
US (4) | US5393763A (en) |
EP (4) | EP1438957B1 (en) |
JP (2) | JP2749247B2 (en) |
KR (1) | KR0161300B1 (en) |
CN (1) | CN1054742C (en) |
AT (2) | ATE359074T1 (en) |
AU (1) | AU658075B2 (en) |
BG (1) | BG61429B1 (en) |
BR (1) | BR9303013A (en) |
CA (1) | CA2101356C (en) |
CY (2) | CY2044B1 (en) |
CZ (1) | CZ281913B6 (en) |
DE (3) | DE69334132T2 (en) |
DK (2) | DK0584952T3 (en) |
ES (2) | ES2283939T3 (en) |
GR (1) | GR3024171T3 (en) |
HK (1) | HK90197A (en) |
HU (1) | HU219233B (en) |
IL (1) | IL106450A (en) |
LU (1) | LU90334I2 (en) |
MX (1) | MX9304432A (en) |
MY (1) | MY111188A (en) |
NL (1) | NL980044I2 (en) |
NO (2) | NO303863B1 (en) |
NZ (3) | NZ314686A (en) |
PH (1) | PH30032A (en) |
PL (1) | PL177348B1 (en) |
PT (1) | PT1438957E (en) |
RO (1) | RO113212B1 (en) |
RU (1) | RU2104697C1 (en) |
SA (1) | SA93140340B1 (en) |
SG (1) | SG45315A1 (en) |
TW (1) | TW366342B (en) |
UA (1) | UA26213C2 (en) |
ZA (1) | ZA935283B (en) |
Families Citing this family (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) * | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US6395494B1 (en) * | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US6663881B2 (en) | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
WO1996040098A2 (en) * | 1995-06-07 | 1996-12-19 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
ATE406909T1 (en) * | 1993-05-13 | 2008-09-15 | Poniard Pharmaceuticals Inc | PREVENTION AND TREATMENT OF PATHOLOGIES ASSOCIATED WITH ABNORMAL PROLIFERATION OF SMOOTH MUSCLE CELLS |
TW303299B (en) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5441964A (en) * | 1993-10-15 | 1995-08-15 | Eli Lilly And Company | Methods for inhibiting bone loss using substituted benzothiophene |
US6319914B1 (en) | 1993-11-05 | 2001-11-20 | Apollo Biopharmaceuticals, Inc. | Cytoprotective effect of polycyclic phenolic compounds |
US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
US6489355B2 (en) * | 1993-12-01 | 2002-12-03 | Eli Lilly And Company | Methods of inhibiting the effects of amyloidogenic proteins |
RU2135176C1 (en) * | 1993-12-14 | 1999-08-27 | Эли Лилли Энд Компани | Water-dissolved inclusion complex of benzothiophene compounds with water-soluble cyclodextrin, method of synthesis and pharmaceutical composition |
US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
US5441966A (en) * | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting Turner's syndrome |
US5591753A (en) * | 1994-01-28 | 1997-01-07 | Eli Lilly And Company | Combination treatment for osteoporosis |
US5478847A (en) * | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US5972383A (en) * | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5811120A (en) * | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
BR9500758A (en) * | 1994-03-02 | 1995-10-24 | Lilly Co Eli | Pharmaceutical formulations for oral administration |
US6723739B1 (en) | 1994-05-20 | 2004-04-20 | Eli Lilly And Company | Glucopyranoside benzothiophenes |
NZ272608A (en) * | 1994-07-22 | 2000-05-26 | Lilly Co Eli | Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts |
US5502074A (en) * | 1994-08-22 | 1996-03-26 | Eli Lilly And Company | Benzothiophenes for bone healing and fracture repair |
US5512296A (en) * | 1994-08-22 | 1996-04-30 | Eli Lilly And Company | Methods for inhibiting neuronal damage |
US5550123A (en) * | 1994-08-22 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone prosthesis degeneration |
CA2198108A1 (en) * | 1994-08-22 | 1996-02-29 | William Lockridge Sales | Methods of maintaining teeth and oral bone |
US5554628A (en) * | 1994-09-20 | 1996-09-10 | Eli Lilly And Company | Method for minimizing the uterothrophic effect of tamoxifen and tamoxifen analogs |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5589482A (en) * | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
US5494929A (en) * | 1995-01-12 | 1996-02-27 | Eli Lilly And Company | Methods of inhibiting growth hormone effects |
US5489587A (en) * | 1995-01-20 | 1996-02-06 | Eli Lilly And Company | Benzofurans used to inhibit bone loss |
US5512583A (en) * | 1995-01-30 | 1996-04-30 | Eli Lilly And Company | Methods of decreasing serum calcium levels |
US5571808A (en) * | 1995-01-31 | 1996-11-05 | Eli Lilly And Company | Method for treating smoking-related bone loss |
HUP9801829A3 (en) * | 1995-02-06 | 1999-10-28 | Lilly Co Eli | Use of benzotiophene derivatives for producing pharmaceutical compositions for inhibiting effects of il-6 |
US20030083733A1 (en) * | 1997-10-10 | 2003-05-01 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5856340A (en) | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
US5552401A (en) * | 1995-02-28 | 1996-09-03 | Eli Lilly And Company | 2-benzyl-3-arylbenzothiophenes |
JPH08253417A (en) * | 1995-02-28 | 1996-10-01 | Eli Lilly & Co | Pharmaceutical preparation for suppressing estrogen positive tumor of brain or cns |
US6479517B1 (en) | 1995-02-28 | 2002-11-12 | Eli Lilly And Company | Phosphorous-containing benzothiophenes |
ZA961564B (en) * | 1995-02-28 | 1997-08-27 | Lilly Co Eli | Methods of inhibiting ovarian cancer. |
US5705507A (en) * | 1995-03-10 | 1998-01-06 | Eli Lilly And Company | Aplha-substituted-3-benzyl-benzofurans |
US5622974A (en) * | 1995-03-10 | 1997-04-22 | Eli Lilly And Company | α-substituted-3-benzyl-benzofurans |
US6653328B1 (en) | 1995-03-10 | 2003-11-25 | Eli Lilly And Company | 3-benzyl-benzothiophenes |
US6384053B1 (en) | 1995-03-10 | 2002-05-07 | Eli Lilly And Company | α-substituted-1-benzyl-napthyls |
US6395755B1 (en) * | 1995-03-10 | 2002-05-28 | Eli Lilly And Company | Benzothiophene pharmaceutical compounds |
US5523309A (en) * | 1995-03-10 | 1996-06-04 | Eli Lilly And Company | Benzofuran pharmaceutical compounds |
US6451817B1 (en) | 1995-03-10 | 2002-09-17 | Eli Lilly And Company | Alpha-substituted-1-benzyl-napthyls |
US6391892B1 (en) | 1995-03-10 | 2002-05-21 | Eli Lilly And Company | Naphthyl pharmaceutical compounds |
US6417199B1 (en) | 1995-03-10 | 2002-07-09 | Eli Lilly And Company | 3-benzyl-benzothiophenes |
US5514704A (en) * | 1995-03-13 | 1996-05-07 | Eli Lilly And Company | Benzothiophenes to inhibit leukotrienes |
US5514703A (en) * | 1995-03-13 | 1996-05-07 | Eli Lilly And Company | Benzothiophene compounds useful for inhibiting lipoxygenase |
US5532382A (en) * | 1995-03-13 | 1996-07-02 | Eli Lilly And Company | Benzothiophenes substituted at the 3-carbonyl |
US20040167080A1 (en) * | 1995-03-15 | 2004-08-26 | Dodge Jeffrey A. | Glucopyranoside benzothiophenes |
US5563054A (en) * | 1995-03-31 | 1996-10-08 | Eli Lilly And Company | Process for preparation of benzo[B]thiophene glucuronides |
US20020091433A1 (en) * | 1995-04-19 | 2002-07-11 | Ni Ding | Drug release coated stent |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6608090B1 (en) | 1995-04-21 | 2003-08-19 | Eli Lilly And Company | Benzothiophenes with novel basic side chains |
US5622975A (en) * | 1995-06-01 | 1997-04-22 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell migration |
US5843974A (en) * | 1995-06-06 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se |
US5599822A (en) * | 1995-06-06 | 1997-02-04 | Eli Lilly And Company | Methods for minimizing bone loss |
EP0747380B1 (en) * | 1995-06-07 | 1998-09-30 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side chains |
US6545027B1 (en) | 1995-06-07 | 2003-04-08 | Eli Lilly And Company | Methods of modulating NF-kB transcription factor |
AU6335496A (en) * | 1995-06-26 | 1997-01-30 | Eli Lilly And Company | Benzothiophene compounds |
US5726186A (en) * | 1995-09-08 | 1998-03-10 | Eli Lilly And Company | Pentacyclic compounds, intermediates, processes, compositions, and methods |
US5731328A (en) * | 1995-10-10 | 1998-03-24 | Eli Lilly And Company | Methods of inhibiting plasminogen activator inhibitor 1 |
AU761274B2 (en) * | 1996-01-29 | 2003-05-29 | Schering Aktiengesellschaft | Pharmaceutical combination preparation that consists of LHRH-analogues and antiestrogens for treating gynecological disorders |
CZ235398A3 (en) * | 1996-01-29 | 1999-02-17 | Eli Lilly And Company | Pharmaceutical preparation for inhibiting musculoaponeurotic fibromatoses in mammals, particularly humans |
US5670523A (en) * | 1996-01-29 | 1997-09-23 | Eli Lilly And Company | Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors) |
US6113876A (en) * | 1996-01-29 | 2000-09-05 | Eli Lilly And Company | Methods of increasing sphincter competence |
ID15917A (en) * | 1996-01-29 | 1997-08-21 | Lilly Co Eli | METHODS FOR OBLIGATION OF LARGE COLUMN TUMORS |
US6432982B1 (en) | 1996-02-21 | 2002-08-13 | Eli Lilly And Company | Benzothiophenes, and formulations and methods using same |
US5731342A (en) * | 1996-02-22 | 1998-03-24 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
IL120263A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to prevent bone loss-progesterone and estrogen agonists |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
US5688796A (en) * | 1996-03-12 | 1997-11-18 | Eli Lilly And Company | Heterocyclic substituted benzothiophenes, compositions, and methods |
EP0801066A1 (en) * | 1996-03-12 | 1997-10-15 | Eli Lilly And Company | Heterocyclic substituted benzothiophenes and pharmaceutical compositions |
DE69739855D1 (en) * | 1996-03-26 | 2010-06-02 | Lilly Co Eli | BENZOTHIOPHENS AND COMPOSITIONS CONTAINING THEM |
US6458811B1 (en) * | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
US5827876A (en) * | 1996-04-09 | 1998-10-27 | American Home Products Corporation | Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes |
US5811437A (en) * | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
AU727708B2 (en) | 1996-06-20 | 2000-12-21 | Board Of Regents, The University Of Texas System | Compounds and methods for providing pharmacologically active preparations and uses thereof |
CA2206752A1 (en) * | 1996-07-02 | 1998-01-02 | George Joseph Cullinan | Benzothiophene compounds, intermediates, processes, and methods of use |
US5980938A (en) * | 1996-07-15 | 1999-11-09 | Eli Lilly And Company | Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1) |
BR9713176A (en) * | 1996-08-28 | 2000-02-08 | Lilly Co Eli | Amorphous benzothiophenes, methods of preparation and methods of use |
CA2214072C (en) * | 1996-08-29 | 2006-11-14 | Eli Lilly And Company | Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods |
CA2218756A1 (en) * | 1996-10-25 | 1998-04-25 | Kristin Sue Marron | Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators |
GB9624800D0 (en) * | 1996-11-29 | 1997-01-15 | Lilly Co Eli | Methods of preventing breast cancer |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
GB2324726A (en) * | 1997-05-01 | 1998-11-04 | Merck & Co Inc | Combination Therapy for the Treatment of Osteoporosis |
US6096764A (en) * | 1997-08-21 | 2000-08-01 | Eli Lilly And Company | Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration |
ID24978A (en) * | 1997-11-14 | 2000-08-31 | Lilly Co Eli | 2-ARYL-3-AROYLBENZO (b) USE THIOPHENES FOR TREATMENT OF ESTROGEN DEPRIVATION SYNDROME |
US6096781A (en) * | 1997-11-14 | 2000-08-01 | Eli Lilly And Company | 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome |
US6780609B1 (en) | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
KR100620772B1 (en) * | 1998-05-15 | 2006-09-13 | 와이어쓰 | Pharmaceutical composition comprising estrogens and 2-phenyl-1-[4-2-aminoethoxy-benzyl]-indole |
US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
CN1305377A (en) * | 1998-06-16 | 2001-07-25 | 伊莱利利公司 | Methods for increasing levels of acetylcholine |
US6353003B1 (en) * | 1998-06-17 | 2002-03-05 | Eli Lilly And Company | Method for reducing levels of homocysteine and C-reactive protein |
US6258826B1 (en) | 1998-10-13 | 2001-07-10 | Eli Lilly And Company | Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome |
DE19916419B4 (en) * | 1999-04-08 | 2005-06-16 | Schering Ag | Combination preparation of vitamin D metabolites or vitamin D analogues and an estrogen partial agonist for the treatment of osteoporosis |
AU777770C (en) | 1999-05-04 | 2005-11-10 | Strakan International Limited | Androgen glycosides and androgenic activity thereof |
US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
JP4790178B2 (en) | 1999-07-06 | 2011-10-12 | アンドルシェルシュ・インコーポレイテッド | Method for treating and / or suppressing weight gain |
US6339078B1 (en) | 1999-07-20 | 2002-01-15 | University Of Florida Research Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
US6326365B1 (en) | 1999-07-20 | 2001-12-04 | Apollo Biopharmaceutics, Inc. | Methods of prevention and treatment of ischemic damage |
KR100729311B1 (en) | 1999-08-31 | 2007-06-19 | 바이엘 쉐링 파마 악티엔게젤샤프트 | Mesoprogestins Progesterone Receptor Modulators as a Component of Compositions for Hormone Replacement Therapy HRT |
KR100334073B1 (en) * | 1999-10-19 | 2002-04-26 | 김순택 | Electron gun for cathode ray tube |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
AU2002235348A1 (en) * | 2001-01-17 | 2002-07-30 | Praecis Pharmaceuticals Inc. | Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
WO2002094788A1 (en) * | 2001-05-22 | 2002-11-28 | Eli Lilly And Company | 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods |
US6962928B2 (en) * | 2001-05-22 | 2005-11-08 | Eli Lilly And Company | Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis |
US20030216358A1 (en) * | 2001-07-05 | 2003-11-20 | Muchmore Douglas Boyer | Method for enhancing bone mineral density gain |
JP2005504032A (en) | 2001-07-31 | 2005-02-10 | ファイザー・プロダクツ・インク | Pharmaceutical compositions, kits and methods comprising estrogen agonist / antagonist, estrogen and progestin combinations |
EP1312363A1 (en) * | 2001-09-28 | 2003-05-21 | Pfizer Products Inc. | Methods of treatment and kits comprising a growth hormone secretagogue |
EP2266590A3 (en) | 2002-02-22 | 2011-04-20 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US7342884B2 (en) * | 2002-03-13 | 2008-03-11 | Harmonic, Inc. | Method and apparatus for one directional communications in bidirectional communications channel |
US8697029B2 (en) | 2002-04-18 | 2014-04-15 | The Regents Of The University Of Michigan | Modulated physical and chemical sensors |
US20040058458A1 (en) * | 2002-04-18 | 2004-03-25 | The Regents Of The University Of Michigan | Modulated chemical sensors |
JP3887588B2 (en) * | 2002-08-30 | 2007-02-28 | 株式会社リガク | Stress measurement method by X-ray diffraction |
ATE541840T1 (en) * | 2002-09-30 | 2012-02-15 | Gea Farmaceutisk Fabrik As | RALOXIFENE-L-LACTATE OR A HEMIHYDRATE THEREOF, USES THEREOF, PHARMACEUTICAL COMPOSITIONS AND PRODUCTION METHOD |
US20040138180A1 (en) * | 2002-10-03 | 2004-07-15 | Barr Laboratories, Inc. | Bisphosphonate composition and process for the preparation thereof |
US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
EP1667692A1 (en) * | 2003-09-19 | 2006-06-14 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
MXPA06006810A (en) * | 2003-12-17 | 2006-08-23 | Pfizer Prod Inc | Continuous combination therapy with selective prostaglandin ep4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass. |
US20050137264A1 (en) * | 2003-12-22 | 2005-06-23 | Patel Ashish A. | Modafinil compositions |
US20050203086A1 (en) * | 2004-03-04 | 2005-09-15 | Pfizer Inc. | Methods of treatment using an EP2 selective receptor agonist |
US20060068010A1 (en) * | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
EP2098223A1 (en) * | 2004-11-10 | 2009-09-09 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage form |
PT1729735E (en) * | 2004-11-10 | 2007-08-06 | Teva Pharma | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
UA89513C2 (en) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Nanoparticulate raloxifene hydrochloride composition |
JP4761112B2 (en) * | 2005-02-16 | 2011-08-31 | 公益財団法人新産業創造研究機構 | A composition for preventing or treating bone metabolic diseases, comprising a benzofuran derivative |
CN100396667C (en) * | 2006-02-20 | 2008-06-25 | 中国医学科学院医药生物技术研究所 | Unsaturated five heterocycle compound for up-regulating bone formation protein BMP-2 expression activity |
US9068977B2 (en) * | 2007-03-09 | 2015-06-30 | The Regents Of The University Of Michigan | Non-linear rotation rates of remotely driven particles and uses thereof |
UA96076C2 (en) | 2007-10-16 | 2011-09-26 | Репрос Терапьютикс Инк. | Use of trans-clomiphene |
US20090104206A1 (en) * | 2007-10-19 | 2009-04-23 | Mark Zamoyski | Bone microenvironment modulated migraine treatments |
CL2008003799A1 (en) * | 2007-12-21 | 2009-12-18 | Synthon Bv | Pharmaceutical composition comprising raloxifene in immediate release tablet form; Useful for the treatment and / or prevention of osteoporosis. |
WO2009082437A2 (en) | 2007-12-21 | 2009-07-02 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (sarms) and uses thereof |
WO2009146097A1 (en) * | 2008-04-02 | 2009-12-03 | Dr. Reddy's Laboratories Ltd. | Raloxifene pharmaceutical formulations |
WO2009126662A1 (en) * | 2008-04-08 | 2009-10-15 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator |
ES2437916T3 (en) | 2009-07-02 | 2014-01-15 | Synthon B.V. | Raloxifene composition |
WO2011099942A1 (en) | 2010-02-09 | 2011-08-18 | Silverstone Pharma | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy |
DE102010030538A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
US8846331B2 (en) | 2010-08-27 | 2014-09-30 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation sensing systems and methods |
US9816993B2 (en) | 2011-04-11 | 2017-11-14 | The Regents Of The University Of Michigan | Magnetically induced microspinning for super-detection and super-characterization of biomarkers and live cells |
US9289467B2 (en) * | 2011-08-10 | 2016-03-22 | Case Western Reserve University | Compositions and methods for treating bone conditions |
DE102011087987A1 (en) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
MX2014007198A (en) | 2011-12-16 | 2014-10-13 | Olema Pharmaceuticals Inc | Novel benzopyran compounds, compositions and uses thereof. |
JP2015508825A (en) | 2012-02-29 | 2015-03-23 | レプロス セラピューティクス インコーポレイティド | Combination therapy to treat androgen deficiency |
US9797817B2 (en) | 2012-05-03 | 2017-10-24 | The Regents Of The University Of Michigan | Multi-mode separation for target detection |
IN2013MU00665A (en) | 2013-03-05 | 2015-07-03 | Cipla Ltd | |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
US9983110B2 (en) | 2013-11-04 | 2018-05-29 | The Regents Of The University Of Michigan | Asynchronous magnetic bead rotation (AMBR) microviscometer for analysis of analytes |
WO2015108988A2 (en) | 2014-01-17 | 2015-07-23 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
CN106572997A (en) | 2014-05-30 | 2017-04-19 | 辉瑞公司 | Carbonitrile derivatives as selective androgen receptor modulators |
HUE055321T2 (en) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
US11633382B2 (en) | 2015-11-10 | 2023-04-25 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen |
US10118910B2 (en) | 2015-12-09 | 2018-11-06 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
CN109789143A (en) | 2016-07-01 | 2019-05-21 | G1治疗公司 | Antiproliferative based on pyrimidine |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
CN110177554B (en) | 2017-01-06 | 2023-06-02 | G1治疗公司 | Combination therapy for the treatment of cancer |
CN110461853A (en) | 2017-02-10 | 2019-11-15 | G1治疗公司 | Benzothiophene estrogenic agents |
AU2018228279A1 (en) | 2017-03-03 | 2019-09-19 | The University Of Newcastle | Markers of tissue aging and uses therefor |
CN110913861B (en) | 2017-06-29 | 2024-01-09 | G1治疗公司 | Morphological forms of G1T38 and methods of making the same |
CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4185108A (en) * | 1977-05-10 | 1980-01-22 | Westwood Pharmaceuticals Inc. | Antiosteoporotic agents |
EP0062503A1 (en) | 1981-04-03 | 1982-10-13 | Eli Lilly And Company | Benzothiophene compounds and process for preparing them |
ZA822247B (en) | 1981-04-03 | 1983-11-30 | Lilly Co Eli | Benzothiophene compounds and process for preparing them |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
IL65379A0 (en) | 1981-04-03 | 1982-05-31 | Lilly Co Eli | Process for preparing acylated benzothiophenes |
EP0068563A3 (en) * | 1981-06-23 | 1983-06-15 | THE PROCTER & GAMBLE COMPANY | Heterocyclic acetic acid compounds and compositions for treating bone diseases |
US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
US4970237A (en) * | 1987-03-20 | 1990-11-13 | Yale University | Use of clomiphene to increase bone mass in premenopausal women |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5208031A (en) * | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
US5011853A (en) * | 1989-08-25 | 1991-04-30 | Washington University | Compounds for treatment of cholinergic neurotoxins |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
DE4117512A1 (en) * | 1991-05-25 | 1992-11-26 | Schering Ag | 2-PHENYLBENZO (B) FURANES AND THIOPHENES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
JP3157882B2 (en) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | New benzothiophene derivatives |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
US5445941A (en) * | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
ES2105525T3 (en) * | 1993-06-24 | 1997-10-16 | Lilly Co Eli | 2-PHENYL-3-AROILBENZOTIOFENOS ANTIESTROGENIC AS HYPOGLYCEMIC AGENTS. |
TW303299B (en) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
US5441947A (en) * | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
US5468773A (en) * | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
US5457116A (en) * | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods of inhibiting uterine fibrosis |
US5461065A (en) * | 1993-10-15 | 1995-10-24 | Eli Lilly And Company | Methods for inhibiting endometriosis |
RU2135176C1 (en) | 1993-12-14 | 1999-08-27 | Эли Лилли Энд Компани | Water-dissolved inclusion complex of benzothiophene compounds with water-soluble cyclodextrin, method of synthesis and pharmaceutical composition |
US5462949A (en) * | 1993-12-21 | 1995-10-31 | Eli Lilly And Company | Methods of inhibiting fertility in women |
US5591753A (en) | 1994-01-28 | 1997-01-07 | Eli Lilly And Company | Combination treatment for osteoporosis |
US5972383A (en) | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5478847A (en) * | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US5811120A (en) * | 1994-03-02 | 1998-09-22 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
US5629425A (en) * | 1994-09-19 | 1997-05-13 | Eli Lilly And Company | Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene |
CO4410191A1 (en) * | 1994-09-19 | 1997-01-09 | Lilly Co Eli | SYNTHESIS OF 3- [4- (2-AMINOETOXI) BENZOIL] -2-ARYL-6- HYDROXYBENZO [b] THIOPHENES |
US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
US6713494B1 (en) | 1996-08-28 | 2004-03-30 | Eli Lilly And Company | Amorphous benzothiophenes, methods of preparation and methods of use |
ID24978A (en) | 1997-11-14 | 2000-08-31 | Lilly Co Eli | 2-ARYL-3-AROYLBENZO (b) USE THIOPHENES FOR TREATMENT OF ESTROGEN DEPRIVATION SYNDROME |
US6096781A (en) | 1997-11-14 | 2000-08-01 | Eli Lilly And Company | 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome |
US6258826B1 (en) | 1998-10-13 | 2001-07-10 | Eli Lilly And Company | Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome |
-
1993
- 1993-01-12 TW TW082100153A patent/TW366342B/en not_active IP Right Cessation
- 1993-07-21 ZA ZA935283A patent/ZA935283B/en unknown
- 1993-07-21 NZ NZ314686A patent/NZ314686A/en not_active IP Right Cessation
- 1993-07-21 NZ NZ248210A patent/NZ248210A/en not_active IP Right Cessation
- 1993-07-22 MX MX9304432A patent/MX9304432A/en unknown
- 1993-07-22 BG BG97982A patent/BG61429B1/en unknown
- 1993-07-22 IL IL10645093A patent/IL106450A/en not_active IP Right Cessation
- 1993-07-22 PH PH46555A patent/PH30032A/en unknown
- 1993-07-22 NO NO932650A patent/NO303863B1/en not_active IP Right Cessation
- 1993-07-23 UA UA93003166A patent/UA26213C2/en unknown
- 1993-07-23 CZ CZ931498A patent/CZ281913B6/en not_active IP Right Cessation
- 1993-07-26 EP EP04101615A patent/EP1438957B1/en not_active Revoked
- 1993-07-26 EP EP97200262A patent/EP0781555A1/en not_active Withdrawn
- 1993-07-26 DK DK93305860.4T patent/DK0584952T3/en active
- 1993-07-26 ES ES04101615T patent/ES2283939T3/en not_active Expired - Lifetime
- 1993-07-26 SG SG1996003394A patent/SG45315A1/en unknown
- 1993-07-26 DE DE69334132T patent/DE69334132T2/en not_active Expired - Lifetime
- 1993-07-26 DE DE69310288T patent/DE69310288T2/en not_active Expired - Lifetime
- 1993-07-26 EP EP07100202A patent/EP1772150A1/en not_active Ceased
- 1993-07-26 DE DE1999175012 patent/DE19975012I2/en active Active
- 1993-07-26 AT AT04101615T patent/ATE359074T1/en active
- 1993-07-26 AT AT93305860T patent/ATE152351T1/en active
- 1993-07-26 EP EP93305860A patent/EP0584952B1/en not_active Expired - Lifetime
- 1993-07-26 DK DK04101615T patent/DK1438957T3/en active
- 1993-07-26 ES ES93305860T patent/ES2102602T3/en not_active Expired - Lifetime
- 1993-07-26 PT PT04101615T patent/PT1438957E/en unknown
- 1993-07-26 HU HU9302163A patent/HU219233B/en unknown
- 1993-07-27 PL PL93299814A patent/PL177348B1/en unknown
- 1993-07-27 RU RU93048466A patent/RU2104697C1/en active
- 1993-07-27 MY MYPI93001475A patent/MY111188A/en unknown
- 1993-07-27 KR KR1019930014329A patent/KR0161300B1/en not_active IP Right Cessation
- 1993-07-27 AU AU44221/93A patent/AU658075B2/en not_active Expired
- 1993-07-27 CA CA002101356A patent/CA2101356C/en not_active Expired - Lifetime
- 1993-07-27 BR BR9303013A patent/BR9303013A/en not_active Application Discontinuation
- 1993-07-28 CN CN93117097A patent/CN1054742C/en not_active Ceased
- 1993-07-28 RO RO93-01066A patent/RO113212B1/en unknown
- 1993-07-28 JP JP5185965A patent/JP2749247B2/en not_active Expired - Lifetime
- 1993-11-13 SA SA93140340A patent/SA93140340B1/en unknown
-
1994
- 1994-01-12 US US08/180,522 patent/US5393763A/en not_active Ceased
- 1994-10-26 US US08/329,396 patent/US5457117A/en not_active Ceased
-
1995
- 1995-04-14 US US08/422,096 patent/US5534527A/en not_active Expired - Lifetime
-
1997
- 1997-06-26 HK HK90197A patent/HK90197A/en not_active IP Right Cessation
- 1997-07-18 GR GR970401816T patent/GR3024171T3/en unknown
- 1997-09-24 JP JP25893797A patent/JP3162662B2/en not_active Expired - Lifetime
-
1998
- 1998-04-30 CY CY9802044A patent/CY2044B1/en unknown
- 1998-12-23 NL NL980044C patent/NL980044I2/en unknown
- 1998-12-23 LU LU90334C patent/LU90334I2/en unknown
-
1999
- 1999-04-14 NO NO1999006C patent/NO1999006I1/en unknown
-
2000
- 2000-05-18 NZ NZ504611A patent/NZ504611A/en not_active IP Right Cessation
-
2003
- 2003-05-27 US US10/446,210 patent/US6906086B2/en not_active Expired - Fee Related
-
2008
- 2008-08-13 CY CY0800014A patent/CY2599B2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2101356C (en) | Improvements in or relating to benzothiophenes | |
US5464845A (en) | Methods for lowering serum cholesterol | |
EP0659413B1 (en) | Inhibition of CNS problems in post-menopausal women | |
JPH07215858A (en) | Method of suppressing dysfunctional metrorrhagia | |
JPH07215865A (en) | Method for promoting libido of woman after menopause | |
US5451589A (en) | Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism | |
US5698572A (en) | Methods of inhibiting turner's syndrome | |
IL112039A (en) | Benzothiophene derivatives for use in inhibiting breast disorders | |
USRE38968E1 (en) | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride | |
USRE39049E1 (en) | Methods for inhibiting bone loss | |
US20060106010A1 (en) | Methods for inhibiting bone loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |